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Approximately 1-2 billion people are infected with T. gondii globally, making it 
one of the most successful protozoan parasites. With this in mind, we believe it 
is critical to better understand immunogenic ligands that may increase the 
pathogenicity of T. gondii during mammalian infections. Previous research on 
Systemic Lupus Erythematosus (SLE) demonstrated that cl-CD95L aggravates 
inflammation. Therefore, this study will delve into the role of cl-CD95L as an 
aggravating factor in the development of pathogenic T. gondii responses. To carry 
out this investigation VERO cells were used to deliver preliminary results on the 
impact cl-CD95L has on cell viability and cytotoxicity. Following on from this, 
bone-marrow derived macrophages (BMDM) were stimulated with cl-CD95L and 
infected with T. gondii. BMDM cultures were analysed to uncover through which 
pathways cl-CD95L may lead to an increase in parasitemia during infection. 
Finally, a Phospho-Kinase Array was utilized and determined that cl-CD95L 
amplifies protein expression in non-infected BMDM. Interestingly, the proteins 
expressed are similar to those of a myeloid-derived suppressor cell (MDSC). From 
the data collected we believe that cl-CD95L causes an MDSC like phenotype in 
previously un-polarized BMDM. The hallmark of MDSC activity is the increase in 
Arginase-1 expression which leads to the depletion of L-arginine, this in turn 
decreases the immune response against T. gondii, leading to an increase in 
parasite replication.  
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Chapter 1. Introduction  
1.1. Toxoplasma gondii 
 Toxoplasma gondii is the causative agent of the disease toxoplasmosis, this 
obligate apicomplexan intracellular protozoan parasite is prevalent in most 
warm-blooded animals (Howe and Sibley, 1995). In humans most T. gondii 
infections are asymptomatic however as an opportunistic parasite it is capable of 
causing devastating effects frequently manifesting in the development of brain 
abscesses and encephalitis (Lehmann et al., 2006) (J G Montoya and Liesenfeld, 
2004). T. gondii, therefore, more commonly causes disease in congenitally 
infected infants and immune-compromised adults (Hill and Dubey, 2002). 
There is a vast socio-economic impact of toxoplasmosis especially due to the cost 
of care for those with mental impairment and blindness (Roberts, Murrell and 
Marks, 1994). Routine testing of all pregnant women for T. gondii occurs in some 
European countries such as France while others still debate the cost-benefit of 







1.2.  Life history of T. gondii 
T. gondii is tissue-cyst-forming and uses a prey-predator system in which it 
alternates between intermediate and definitive hosts for asexual and sexual 
reproduction. Not only can T. gondii be transmitted between intermediate and 
definitive hosts but also between intermediate hosts via carnivorism or even 
between definitive hosts (Robert-Gangneux and Dardé, 2012). 
Approximately 30-40% of domestic cats (Felis catus) are infected with T. gondii 
(Webster, 2010). Felidae family members are the definitive hosts of T. gondii and 
sexual reproduction of the parasite occurs in the intestine of the cat (Dubey, 
Lindsay and Speer, 1998). Figure 1 illustrates the lifecycle of T. gondii through its 
definitive and intermediate hosts while also demonstrating different routes of 
infection. 
Bradyzoites invade the epithelial cells of the small intestine where they initiate 
the formation of numerous asexual generations before the sexual cycle begins.  
Bradyzoites are a slow multiplying stage that undergo a self-limiting number of 
asexual multiplications within enterocytes, this is characterised by the 
development of merozoites (Dubey, 1998). Sexual development then follows 
with the formation of both male and female gametes, which fuse and fertilise 
each other (Ferguson, 2002). Oocysts are then formed after fertilisation, within 
enterocytes, these are subsequently liberated from the cell and excreted as the 
unsporulated form in cat faeces (Jones and Dubey, 2010). Following sporulation 
in the environment, sporozoites become infective. Upon the intake of sporulated 
oocysts by an intermediate host, the sporozoites transform into the invasive 
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tachyzoite stages (Dubey, Lindsay and Speer, 1998). The tachyzoites are crescent-
shaped approximately 2-6μm in width and 4-8μm in length, with a pointed 
anterior (apical end) containing secretory organelles and a rounded posterior end 
(Halonen and Weiss, 2013). Locomotion of T. gondii occurs via gliding motility, 
which is instrumental in parasite migration and cellular invasion (Sibley, 
Hâkansson and Carruthers, 1998). Tachyzoites actively penetrate the host cells 
through the cell membrane or by phagocytosis. After entering the host cell, 
tachyzoites are surrounded by a parasitophorous vacuole (Mordue et al., 1999). 
Tachyzoites asexually replicate rapidly by repeated endodyogeny in non-
intestinal epithelial cells of the definitive host and any cell of the intermediate 
host (Dubey, Lindsay and Speer, 1998). The rates of both invasion and growth 
differ depending on the strain of T. gondii (Appleford and Smith, 1997). There are 
three distinct clonal genotypes of T. gondii, type I, II, and III (Howe and Sibley, 
1995). Type I has been shown to be virulent in mice regardless of the host 
genotype and in humans as seen in acquired immune deficiency syndrome (AIDS) 
patients. Whereas, type II is non-virulent to mice while still seen as virulent in 
humans and commonly associated with congenital infections and in patients with 
AIDS (Howe et al., 1997). Finally type III is non-virulent in mice but still virulent in 
other animals although it is less commonly seen in humans (Sibley et al., 2009). 
After the repeated rounds of replication, the host cells are exited and the 
tachyzoites invade neighbouring cells. This host cellular destruction is responsible 




Bradyzoites multiply slowly within a tissue cyst, these tissue cysts grow and 
remain intracellular as the bradyzoites replicate by endodyogeny (Robert-
Gangneux and Dardé, 2012). They are predominantly located in the central 
nervous system (CNS), cardiac and skeletal muscles as well as the eye due to their 
high affinity for neural and muscular tissues (Tenter, Heckeroth and Weiss, 2000). 
These cysts can break down, in turn, releasing bradyzoites. Therefore, in an 
infected animals’ lifetime, the tissue cyst burden constantly evolves and may 
persist for life in some intermediate hosts (Figure 1) (Schlüter et al., 2014). 
 
 
Figure 1. Lifecycle of Toxoplasma gondii. A diagram illustrating the lifecycle of 
Toxoplasma gondii, while also identifying both the infective and diagnostic 
stages (Adapted from the CDC, 2015). 
 
The blue arrows show infection of humans by T. gondii where they act as an intermediate 
host. During pregnancy the parasite can be transmitted across the placenta, infecting the 
foetus. The red arrows show the infection and continued cycling of T. gondii through the 
definitive host, which is the cat (Adapted from the CDC, 2015).  
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1.3. Modes of Transmission 
The life cycle of T. gondii may be able to continue indefinitely by the transmission 
of oocysts between definitive hosts but also by the transmission of tissue cysts 
between intermediate hosts (Tenter, Heckeroth and Weiss, 2000). T. gondii 
infections may be transferred between intermediate hosts including humans 
through the horizontal transmission of viable cysts in the food chain (Montoya 
and Liesenfeld, 2004). T. gondii tissue cysts have been found in a plethora of meat 
products from pigs, lambs and goats, and game (Cenci-Goga et al., 2011). In 
Europe and also the USA the major source of T. gondii in humans is undercooked 
pork (Dubey, 1998). 
Humans can also be infected by oocysts, which have been excreted from the cat 
through the faecal oral route. Oocysts can remain viable as they are resistant to 
external environmental conditions in soil and water (VanWormer et al., 2013). 
The variations of seroprevalence of T. gondii have been found to correlate with 
hygiene and eating habits of a population supporting the oral route as a major 
source of infection (Cook et al., 2000). 
The vertical transmission of tachyzoites from mother to unborn foetus causes 
congenital toxoplasmosis. This occurs when the woman acquires a T. gondii 
infection for the first time during gestation. T. gondii will then enter the foetus 




The frequency of T. gondii transmission increases with the gestational age at the 
point of infection. Consequences to the offspring are severe at the beginning of 
the pregnancy however the trans-placental passage of tachyzoites is rare 
(Robert-Gangneux and Dardé, 2012). 
Congenital toxoplasmosis leads to approximately 4-10% of pregnancies resulting 
in stillbirths, abortion or neonatal deaths (Remington et al., 2006). The incidence 
of congenital toxoplasmosis evaluated varies between different countries with 
the incidence in Brazil at 1 per 3000 live births and in France with 3.3 per 10,000 















1.4. Diagnosis, treatment and prevention  
Toxoplasmosis has nonspecific clinical signs, which mimics a variety of other 
infectious diseases and therefore these alone cannot be relied upon for a definite 
diagnosis (Halonen and Weiss, 2013). Serologic examination can aid the diagnosis 
of a T. gondii infection. The most reliable serologic test is the Sabin-Feldman dye 
test which is used to detect antibodies to T. gondii (Sabin and Feldman, 1948). In 
the case of immunosuppressed or patients with AIDS, the diagnosis of 
toxoplasmosis is made by biopsy findings of T. gondii in host tissue, this is useful 
due to suppressed host antibody synthesis (Montoya, 2002).  
Pyrimethamine is the most effective treatment for toxoplasmosis as it has been 
shown to kill the proliferating tachyzoites both in vitro and in vivo. A second drug 
such as sulfadiazine or trisulfapyrimidines should be used in combination with 
pyrimethamine for the most effective outcome in humans however they do not 
target tissue dwelling bradyzoites (Nath and Sinai, 2003). However, a review of 
114 patients with Toxoplasma encephalitis found drug toxicity in 62% of the 
patients treated with pyrimethamine and sulfadiazine, 44% of which required a 
change in therapy due to severe side effects (Porter and Sande, 1992). 
There is currently no human vaccine available to prevent infections in humans 
although there is a live vaccine that has been shown to reduce abortion in sheep 
(Rorman et al., 2006). Toxovax is based on a live attenuated S48 strain, used in 
sheep across Europe and New Zealand, is unsuitable for human use due to the 
ability of the attenuated parasite to revert to a pathogenic strain(Kur, Holec-
Gąsior and Hiszczyńska-Sawicka, 2009). 
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There is a plethora of public-health measures that can be implemented to reduce 
transmission and the disease burden of T. gondii in both humans and animals. 
The most important risk factor for human infection is known to be uncooked 
meat, therefore, all meat products should be cooked throughout to 56C for 10 
minutes before human consumption. Raw meat should never be fed to cats due 
to the possible presence of tissue cysts while their litter trays should be cleaned 
daily and faecal matter disposed of correctly. While pregnant, cats and livestock 
should be avoided to limit transmission of T. gondii (Hill and Dubey, 2002). A 
European multicentre case-control study found 6-17% of primary T. gondii 
infections were due to soil contact. To reduce contact with soil that may contain 
cat faeces gloves should be used when gardening (Cook et al., 2000). Oocysts are 
capable of remaining viable in water for extended periods of time while being 
resistant to freezing (Robert-Gangneux and Dardé, 2012). There have been 
several outbreaks of toxoplasmosis in humans linked to drinking contaminated 
water (Bowie et al., 1997). It has been found that chemical and physical 
treatments applied during water treatment, including chlorination and ozone 
treatment, are not effective in killing oocysts in the water. However, It has been 
found UV treatment to be an effective method to inactivate oocysts in drinking 





1.5. Cell Biology  
T. gondii mechanisms of target cell invasions are distinct from other intracellular 
microorganisms. Unlike most viruses and intracellular bacteria, T. gondii requires 
no host cell participation but actively penetrates the host cell (Carruthers, 2002). 
T. gondii is capable of invading a variety of host cells in what has been described 
as a three-step process involving the secretion of proteins from secretory 
organelles, the rhoptries, the micronemes and the dense granules at the apical 
tip of the parasite (Carruthers and Sibley, 1997). 
Studies have shown in the absence of these organelles, the invasion is suppressed 
and as a result, a lower number of the intracellular parasites present (Huynh, 
Boulanger and Carruthers, 2014). The first phase is a gliding motility phase, the 
second is the formation of the moving junction and the third is the development 
of the parasitophorous vacuole (Dubremetz, 2007). 
The gliding motility phase allows T. gondii to reach a host cell and make contact 
between the host cell membrane and its apical tip. Gliding motility is promoted 
by dynamic rearrangements of the cytoskeleton and actin-myosin interactions of 
the parasite (Carruthers and Boothroyd, 2007). 
A moving junction is formed starting as initial close contact between the host cell 
membrane and the apical end of T. gondii that quickly turns into a ring encircling 
the parasite. Gliding backward allows entry of T. gondii into the host cell 
membrane, called the moving junction. For the establishment of the moving 
junction, an apical membrane antigen must be distributed across the surface of 
the invading parasite. T. gondii also requires the secretion of rhoptry neck 
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proteins, which are injected into the host cell to function as a receptor for apical 
membrane antigen on the parasite (Alexander et al., 2005). 
The moving junction relocates from the apical end to the posterior end of T. 
gondii, which leads to the internalization of the parasite into the parasitophorous 
vacuole. Dense granular proteins also contribute to the formation of the 
parasitophorous vacuole membrane (PVM) (Nichols, Chiappino and O’Connor, 
1983). 
During the invasion process, most host transmembrane proteins are stripped 
from the PVM. This process prevents fusion with lysosomes as it modifies the 
biochemical characteristics of the PVM. Thereby allowing the parasite to avoid 
destruction by phagolysosomes  (Sinai, 2008). In intermediate hosts, tachyzoites 
divide by endodyogeny within the PVM, forming two daughter cells within each 
mother cell. After approximately 64 to 128 parasites have accumulated in the 
PVM they will exit the cell (Robert-Gangneux and Dardé, 2012). In the definitive 
host, once the female gamete is fertilised and the oocysts mature, they will be 
discharged into the intestinal lumen through the rupturing the epithelial cells 








1.6. The Host immune response to Toxoplasma gondii 
The first step in the host immune response is the detection of infectious non-self, 
which enables the host to mount a response against infection. Initiation of the 
innate immune response begins with the recognition of pathogen-associated 
molecular patterns (PAMPSs) by germline-encoded receptors, which are 
commonly expressed on immune cells called termed pattern recognition 
receptors (PRRs) (Mortaz et al., 2017). There are several classes of PRRs including 
Toll-like receptors (TLRs), which are involved in the pathogenesis of diseases 
(Duffy and O’Reilly, 2016).  
TLRs have been shown to have an important role in non-self-discrimination 
through sensing infection and initiating the innate and adaptive immune 
response (Yarovinsky, Hieny and Sher, 2008). TLRs are strongly associated with 
the pathogenesis of inflammatory and autoimmune diseases (Kawai and Akira, 
2010). Adaptor proteins include myeloid differentiation primary response 88 
(MyD88), which is essential for survival in parasite-infected animals whereas the 






Figure 2. Summary of toxoplasmacidal pathways in humans (Adapted from 
Molan et al., 2016). 
 
The classical stimulation pathway of TLRs activates nuclear factor κB (NF-κB) and 
mitogen-activated protein kinases (MAPK) via the Interleukin-1 receptor-
associated kinase 1 (IRAK) complex. The proinflammatory signalling pathway of 
TLRs activates the production of inflammatory cytokines and chemokines 
including IL-1β, IL-6 (Mortaz et al., 2017). Figure 2 illustrates the pathways in 
which T. gondii activated the innate immune response and later the adaptive 







1.7. Innate immunity to Toxoplasma gondii 
On initial infection, T. gondii, triggers the activation of macrophages and natural 
killer (NK) cells along with other haematopoietic and non-haematopoietic cells. 
Parasite proliferation will be limited by the host due to innate cytotoxic action 
(Filisetti and Candolfi, 2004). 
To control the acute phase of T. gondii infection the early production of IL-12 by 
neutrophils, macrophages, and dendritic cells is crucial. A knockout (KO) of the 
MyD88 gene has been shown to impair IL-12 production leading to increased 
susceptibility of mice to T. gondii. Due to uncontrolled parasite replication mice 
succumb to acute infection, dying within 13-16 days post infection in comparison 
to their control counterparts which survived >60 days post infection (Scanga et 
al., 2002). IL-12 stimulates interferon-gamma (IFN- γ) secretion from NK cells and 
T-cells, which is crucial following infection by T. gondii (Khan, Matsuura and 
Kasper, 1994). Once IL-12 binds to its receptor this leads to the activation of the 
signal transducer and activator of transcription 4 (STAT4) signalling cascade, 
which is essential for IFN-γ production (Maier et al., 2002). This has been 
confirmed in STAT4 KO mice, which are susceptible to acute infection with T. 
gondii due to the reduction of IFN- γ production (Cai et al., 2000). The importance 
of IL-12 and its relationship with IFN- γ has also been shown by antibody 
neutralisation of IL-12, which results in 100% mortality of mice that were infected 
with T. gondii, and decreased production of IFN-γ was associated with this 
increased mortality (Gazzinelli et al., 1994).  
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IFN- γ has a multitude of biological activities, which includes the activation of NK 
cells and macrophages (Filisetti and Candolfi, 2004). It has been suggested that 
high levels of IFN-γ are correlated with infection with virulent strains of T. gondii 
and increased apoptosis (Gazzinelli et al., 1996). SCID mice possess an IFN-γ-
dependent mechanism of resistance to intracellular T. gondii. This is dependent 
on the innate production of IFN-γ by NK cells, which is induced by IL-12 (Hunter, 
Chizzonite and Remington, 1995). Studies have shown IFN-γ KO mice have 
impaired IL-12 responses to T. gondii, in which the mice fail to control acute 
infection with mortality being associated with uncontrolled tachyzoites 
replication (Scharton-Kersten et al., 1996).IFN-γ stimulation induces expression 
of p47 guanosine triphosphate family members, of which IGTP, LRG47, and IRG47 
are essential for acute or chronic resistance to T. gondii respectively (Collazo et 
al., 2001). Both IL-12 and IFN-γ direct Th1 differentiation during a primary 
immune response. T Helper type 1 (Th1) cells have also been shown to regulate 
their own response by producing IFN-γ in a positive feedback loop 









Inducible nitric oxide synthase (iNOS) plays an important role in the primary pro-
inflammatory response in macrophages upon pathogen infection (Wang et al., 
2009). There are two major pathways, which are known to influence iNOS gene 
expression within macrophages. These are the Janus kinase and STAT pathway, 
together known as the JAK/STAT pathway and the MAPK pathway. IFN-γ activates 
JAK/STAT pathway, which leads to the activation of the interferon regulatory 
factor-1 (IRF1) and the formation of phosphorylated STAT1 dimers that are key 
transcription factors in the regulation of iNOS transcription (Salim, Sershen and 
May, 2016). iNOS inhibition results in the suppression of the immune response 
against intracellular parasites (El Kasmi et al., 2008).  
 
Macrophages and mast cells produce tumour necrosis factor -α (TNF-α), which 
stimulates microbicidal activity against T. gondii in macrophages that have been 
primed by IFN-γ (Hunter, Chizzonite and Remington, 1995). TNF-α decreases 
intracellular levels of T. gondii by inducing lysosomal fusion of the 
parasitophorous vacuole (De Titto, Catterall and Remington, 1986). TNF-α boosts 
NO to act in a positive feedback loop, triggering iNOS-dependent T. gondii control 
(Masek and Hunter, 2013). After treating macrophages with anti-TNF- α 
antibodies and stimulating with IFN- γ, the production of reactive nitrogen 





IL-6 is expressed by antigen presenting cells including dendritic cells and 
macrophages but it is also produced by a number of non- haematopoietic cells 
such as epithelial cells and keratinocytes. The production of IL-6 can be induced 
in response to external stimuli including IL-1 and TNF-α (Arango Duque and 
Descoteaux, 2014). IL-6 elicits a pro-inflammatory response when it binds to the 
heterodimeric receptor, glycoprotein 130 (gp130). During T. gondii infection IL-6 
–mediated gp130 signalling blocks the generation of protective immunity (Silver 
et al., 2011). Cytokines such as IL-6 have the capability to activate STAT3, which 
limits IL-12 production to prevent an infection-associated immune pathology, 
however, T. gondii uses the activation of STAT3 to evade the host immune 
response. Suppressor of cytokine signalling molecule 3 (SOCS3), which is a target 
of STAT3, has been shown to limit IL-6 signalling. SOCS3 is up-regulated during T. 
gondii infection, without the up-regulation of SOCS3, IL-6 signalling will not be 
suppressed which leads to the uncontrolled replication of T. gondii (Whitmarsh 
et al., 2011). Dienz and colleagues have shown that IL-6 can modulate the Th1-
Th2 balance towards T Helper type 2 (Th2) differentiation. IL-6 inhibits Th1 
differentiation by directly up-regulating IL-1 production but also by inducing the 
expression of SOCS during the activation of CD4+ T cells which interferes with IFN-
γ signalling and production (Dienz and Rincon, 2009). IL-6 KO mice infected with 
T. gondii suffer from more severe tissue damage, increased incidence of 




IL-1β is a member of the interleukin-1 family of cytokines, which is mainly 
produced by monocytes and macrophages. The IL-1β cytokine family members 
are under transcriptional control, however, these cytokines differ from other 
cytokines in that they lack a leader sequence and they are expressed as 
biologically inactive preforms in the cytoplasm of cells (Latz, 2010). These 
cytokine preforms are the substrates of the cysteine protease caspase-1, which 
mediates the cleavage and release of the mature, biologically active cytokine 
forms. Caspase-1 itself is present as an inactive proform in the cytoplasm and it 
is activated by proteolytic self-processing (Thornberry et al., 1992). Several 
multimolecular proteins complexes, referred to as inflammasomes, have been 
identified as caspase-1 activators, which are required of IL-1β cytokine activation 
(Latz, 2010).  
IL-1β is a highly inflammatory cytokine and is also involved in a plethora of cellular 
activities, including cell proliferation, differentiation, and apoptosis (Netea et al., 
2015). IL-1β enhances T cell activation and antigen recognition and has been 
reported to induce the development of Th17 cells (van de Veerdonk and Netea, 
2013). It has been shown during in vitro Toxoplasma infection of macrophages 
activates the nucleotide-binding domain and leucine-rich repeat containing a 
pyrin domain-3 (NLRP-3) inflammasome, resulting in the rapid production and 
cleavage of IL-1β (Gorfu et al., 2014). T. gondii dense granule proteins GRA18, 
GRA27, and GRA28 are essential for the activation of NLRP1 inflammasome. The 
activation of the NLRP1 inflammasome in rats causes pyroptosis,  preventing 
parasite replication within the host cell (Cirelli, 2016). 
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1.8. Classically and alternatively activated macrophages 
Macrophages play a pivotal role in homeostasis and defence and are a widely 
distributed immune cell (Martinez et al., 2008). Macrophages react to a wide 
variety of external stimuli and are able to produce a multitude of effector 
molecules for intercellular communication, microbial defence, and modulation of 
inflammatory reactions. They induce, suppress, or modulate both innate and 
adaptive immune responses (Rath et al., 2014).  M1/M2 describes the two major 
and opposing activities of macrophages. M1 cause tissue damage while actively 
inhibiting cell proliferation. On the other hand, M2 cause tissue repair and 
actively promotes cell proliferation. The names M1 and M2 were chosen because 
M1 and M2 macrophages promote Th1 and Th2 responses, respectively (Mills, 
2012). 
Macrophage metabolism of L-Arginine is an important parameter to identify 
classically and alternatively activated macrophages (Bronte and Zanovello, 2005). 
L-Arginine is an essential amino acid, which is used for the biosynthesis of 
proteins, creatine, and agmatine. It is metabolised by the enzymes iNOS and 
arginase 1 (Arg-1), which produces urea and L-ornithine, and nitric oxide and L-
citrulline(Bronte and Zanovello, 2005). NOS and Arg-1 are competitively 
regulated by both Th1 and Th2 cytokines but also by complex intracellular 
biochemical pathways (Noël et al., 2004). 
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The cytokine IFN-γ drives the classical pathway of macrophage activation and is 
produced by Th1 cells. IFN-γ increases NO release through NOS2 activity and 
inhibits IL-4- or IL-10-driven Arg-1 activity (Martinez and Gordon, 2014). 
Cytokines produced by Th2 cells including IL-4, IL-10, and IL-13, regulate the 
alternative activation of macrophages. Each of these cytokines induces Arg-1 
synthesis and inhibits NOS2 activity (Menzies et al., 2011). 
Murine infections with Leishmania major have demonstrated that in 
macrophages, a Th1 response induces NO synthesis and parasite killing, whereas 
Th2 cytokines inhibits NO synthesis and enables parasite growth. Supporting the 
idea that host arginase activity can promote parasite spread, macrophages were 
infected with L. major and treated with Th2 cytokines, which are all inducers of 
arginase. This lead to a proportional increase in the number of intracellular 
parasites (Modolell et al., 2009). 
T gondii induces NO production by macrophages, which is essential for parasite 
regulation. T.gondii infected Arg-1 KO mice had an improved ability to combat 
infection. However, T. gondii supresses NO production by utilising host arg-1 








1.9. Adaptive immune responses 
During the chronic stage of T. gondii infections, parasite latency is maintained by 
the adaptive T cell response.  Both CD4+ and CD8+ T lymphocytes are involved in 
the host resistance against T. gondii infections (Filisetti and Candolfi, 2004). 
Athymic nude mice lack T cells and are therefore extremely susceptible to both 
virulent and avirulent strains of T. gondii (Langermans et al., 1992).  
Major histocompatibility complex (MHC) molecules are cell surface proteins 
where their function is to present antigenic peptides to T cells (Janeway et al., 
2001). Toxoplasma also interferes with the IFN‐γ‐induced MHC class I and MHC 
class II expression on the cell surface of bone marrow‐derived murine 
macrophages (Luder et al., 1998). Importantly, the inhibition of MCH class II 
expression by antigen‐presenting cells influences CD4+ T cell activation and 
proliferation (Munoz, Liesenfeld and Heimesaat, 2011). 
CD4+ T helper cells are crucial regulators of the adaptive immune response and 
inflammatory diseases. Antigen-specific CD4+ T cells are activated by antigen-
presenting cells and then differentiate into specialised effector cells that secrete 
cytokines (Dong, 2006)(Gazzinelli et al., 1992). CD4+ T lymphocytes can be 
categorised into the sub-populations, Th1, Treg, Th17, and Th2. The 
differentiation of naïve CD+ T cells into Th1 cells is promoted by IL-12 (Salim, 
Sershen and May, 2016). Th1 cells produce IFN-γ and are key in cell-mediated 
immunity due to their ability to activate phagocytes and the production of 
opsonizing and complement-fixing antibodies (Santarlasci et al., 2013). T. gondii 
infections cause a strong Th1 immune response with high levels of IFN-γ and TNF- 
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α, which activate macrophage functions. This is important for the control of 
tachyzoite replication during acute and chronic phases of infection (Denkers and 
Gazzinelli, 1998). In mice, chronically infected with an avirulent stain of T. gondii, 
treatment with anti-IFN-γ antibodies caused reactivation of infection leading to 
death of the all animals. Similar results were also seen in mice treated with anti-
CD4+ showing that both CD4+ and IFN-γ prevent reactivation of latent infections 
(Gazzinelli et al., 1992). 
 
Regulatory T cells (Treg) have been shown to play an important role in 
establishing and maintaining immunological tolerance. However, they also have 
a negative impact on suppressing antitumor responses (Halim et al., 2017). 
Human Tregs have been characterised by their expression CD25, IL-2 receptor 
and the transcription factor FoxP3 (Ziegler, 2007). Studies have shown that Treg 
cells mediate the T‐cell suppression observed during acute T. gondii infection 
through an IL‐2‐dependent mechanism (Tenorio et al., 2011). Following a T. 
gondii infection, the highly Th1 cell‐polarized immune response was associated 
with a collapse in the number of Treg cells via multiple pathways, including the 
blockade of Treg cell induction and disruption of endogenous Treg cell 
homeostasis. In particular, the shutdown of IL‐2 production contributed to Treg 
cell incapacity to suppress effector responses and eventually led to 




Th17 cells were identified as a new subpopulation of T helper cells that secrete 
IL-17 (Yao et al., 1995). Th17 cells are inhibited by the cytokines produced by Th1 
and Th2 cells, IFN-γ and IL-4 (Tesmer et al., 2008). Th17 cells produce cytokines 
and transcription factors that can have both beneficial and pathogenic effects 
(Bailey et al., 2014). Th17 cells and IL-17 expression has been associated with 
many inflammatory diseases in humans, such as systemic lupus erythematosus 
(Tabarkiewicz et al., 2015). Following a T. gondii infection an increase in IL-17 
production has been found to contribute to fatal T. gondii associated 
inflammation (Guiton et al., 2010). However, studies have also shown in IL-17 KO 
mice, their susceptibility to T. gondii infection increases and display a high 
parasite burden and a low neutrophil influx, resulting in increased mortality from 












1.10. CD95 and its ligand CD95L 
CD95 is a member of the tumour necrosis factor (TNF) receptor superfamily, 
which is expressed in a wide range of tissues (Dunay and Sibley, 2010). CD95 has 
an essential role in the elimination of cells that have been infected and ensuring 
immune tolerance to self-antigens (Tauzin et al., 2011). However, the expression 
of its ligand (CD95L), which is a type II transmembrane protein of the TNF family, 
is limited to certain cell types including macrophages and T-cells (Li-Weber and 
Krammer, 2002). When membrane-bound CD95L binds to CD95, the intracellular 
region of CD95 orchestrates the formation of a death-inducing signalling 
complex. This is through the recruitment of the adaptor molecule, Fas-associated 
protein with death domain (FADD), which in turn induces caspase-8 aggregation 
and subsequent apoptosis (Khadra et al., 2011). The expression of CD95L is tightly 
controlled, being expressed primarily at the surface of activated NK cells, 
macrophages, and T cells. However, CD95L can also be found at the surface of 
macrophages, epithelial cells or dendritic cells under inflammatory conditions 
(Penna et al., 2012). Failure of CD95/CD95L signalling leads to an increased risk 
of cancer and autoimmunity (Tauzin et al., 2011). The ligation of CD95 also plays 
critical roles during infection due to the activation of an apoptotic cascade. 
Parasite-induced apoptosis decreased significantly in CD95L KO mice. T. gondii 
causes cell resistance to a plethora of apoptotic inducers, in particular the 
parasite significantly reduces CD95-mediated apoptosis.  It has been found that 
T. gondii blocks CD95-triggered apoptosis by caspase 8 inactivation however, the 
exact molecular mechanism through which T. gondii does so awaits clarification 
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(Vutova et al., 2007). During infection with T. gondii, studies demonstrated that 
when using RH strain there were higher levels of apoptosis of the spleen in 
comparison to avirulent strains however; the proportion of infected cells did not 
rise above 2%. This suggests that the parasite is inducing apoptosis rather than 
an immunopathological basis causing programmed cell death (Gavrilescu and 
Denkers, 2001).  
The extracellular domain of CD95L comprises a juxta-membrane stalk region, 
which is cleavable by metalloprotease, this cleavage releases CD95L into the 
bloodstream. cleaved-CD95L (cl-CD95L) promotes the formation of a motility-
inducing signalling complex, which stimulates non-apoptotic signalling pathways 
and increases the levels of intracellular calcium content, leading to cellular 















Figure 3. Summary of the pathogenic functions of cl-CD95L. Diagram illustrating 
the tight positive-feedback amplification loop for the pathogenic functions of 
cl-CD95L (Poissonnier  et al., 2016). 
 
Figure 3 illustrates the inflammation amplification loop caused by the cleavage of 
CD95L and the mechanisms that allow it to be an aggravating factor in Lupus 
patients. Mechanistically, as cl-CD95L binds to CD95, PLCγ1 is triggered and there 
is a rise in Ca2+ signals promoting the endothelial transmigration of Th17 cells at 
the expense of the T regulatory cells (Poissonnier  et al., 2016). Furthermore, 
Th17 cells are found to up-regulate the expression of PSGL-1 adhesion molecule 
when exposed to cl-CD95L. PSGL-1 is known to promote lymphocyte and 
endothelial tethering and also can provoke secretion of effector cytokines in 
differentiated T cells (Figure 3) (Baaten et al., 2013).  
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cl-CD95L has been found to aggravate the inflammatory process in systemic lupus 
erythematosus (SLE) patients, a chronic autoimmune disorder, whose 
pathogenesis can affect almost all organs and tissues. This happens by the 
recruitment of Th17 cells into organs that are inflamed. The abnormal migration 
of Th17 cells to inflamed organs promotes SLE pathogenesis and tissue 
destruction through immune complex deposition (Poissonnier  et al., 2016). 
Abnormal or elevated levels of cl-CD95L could be an aggravating factor in the 
development of pathogenic T. gondii specific T-cell responses where Th17 cells 
















1.11. Myeloid-derived suppressor cells 
Myeloid-derived suppressor cells (MDSCs) are a unique component of the 
immune system regulating immune responses in both healthy individuals and as 
part of various diseases (Gabrilovich and Nagaraj, 2009). MDSCs are rare in a 
healthy individuals however, may occur naturally in cases of sepsis or trauma to 
suppress the T-cell response (Tamadaho, Hoerauf and Layland, 2017). MDSCs 
have also been found to accumulate in the setting of many tumours and are 
associated with poor clinical outcomes and prognosis (Lechner, Liebertz and 
Epstein, 2010).  
MDSCs are a heterogeneous population of myeloid origin (Gabrilovich and 
Nagaraj, 2009). MDSCs are composed of myeloid cells, immature myeloid cells, 
immature granulocytes, dendritic cells and monocytes-macrophages (Greten, 
Manns and Korangy, 2011). They may be further subdivided into two major types, 
firstly CD11b+Gr-1low monocytic MDSC and CD11b+Gr-1high granulocytic MDSC 
(Youn and Gabrilovich, 2010).  
Several different factors have been found which can influence the expansion and 
activation of MDSCs including IL-6 vascular endothelial growth factor (VEGF-CSF), 
granulocyte/macrophage CSF (GM-CSF) and prostaglandins (Talmadge and 
Gabrilovich, 2013). These trigger the STAT3 pathway, STAT3 signalling has been 
implicated in the stimulation of myeloid cell differentiation into MDSCs. STAT3 
interacts with CCAAT-enhancer-binding protein β (C/EBPβ). C/EBPβ has a key role 
in myeloid development, as C/EBPβ-deficient bone marrow cells lose the ability 
to differentiate into functional MDSCs (Thornberry et al., 1992)(Zhang et al., 
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2010). The activation of immature myeloid cells during pathological conditions 
leads to the expression of their immune suppressive factors to be upregulated 
(Barnie et al., 2017). The combined effect of inducible iNOS and arginase 1 
mediated local arginine deletion leads to the expansion of MDSCs (Lechner, 
Liebertz and Epstein, 2010). MDSCs are best known for their capacity to inhibit T-
cell proliferation. The metabolism of L-arginase has been linked to the 
suppressive activity of MDSC as well as mature macrophages (Dilek et al., 2012). 
MDSC will actively migrate to the site of a tumour where they will upregulate 
arginase 1 and iNOS expression while ROS production is downregulated. The 
levels of both NO and arginase 1 which are produced by a tumour associated 
MDSCs are higher than those found in the peripheral lymphoid organs of the 
same animal (Gabrilovich and Nagaraj, 2009) NO produced by MDSCs suppress T-
cell function by the inhibition of JAK3 and STAT5 functions in T cells, the inhibition 
of the expression of MHC class II and inducing apoptosis of T-cells (Nagaraj and 
Gabrilovich, 2012). In an acute infection iNOS KO mice, which are unable to 
produce NO, control parasite growth at the site of inoculation. However, iNOS KO 
mice eventually succumb to chronic T. gondii infections showing that NO 
production is essential for long-term control of the parasite (Scharton-Kersten et 
al., 1997). In MDSCs the increased activity of arginase 1 leads to the enhanced 
catabolism of L-arginine. This causes a depletion of L-arginine in the 





1.12. Research Rationale  
To date there has been no previous research conducted on the impact of cl-CD95L 
during a parasitic infection. However, other studies have demonstrated that cl-
CD95L leads to non-apoptotic signalling pathways which have been shown to be 
an aggravating factor in autoimmune inflammation, mediated by Th17 responses. 
Therefore, the objective of this study is to investigate if cl-CD95L creates a 
favourable host niche for T. gondii and the consequences of this for the 
subsequent immune response. This understanding of the immune environment 
created during infection could facilitate future success in host-directed 
therapeutics in the treatment of T. gondii. 
 
1.13. Aims 
The aims of this project are therefore to: 
 
1. Investigate cl-CD95L in relation to altered Toxoplasma gondii burden. 
2. To investigate if cl-CD95L alters cellular responses after Toxoplasma 
gondii interaction. 




Chapter 2. Materials and Methods  
2.1. Vero cell cultures 
Vero cells are a commonly used cell line which were originally isolated from 
kidney epithelial cells extracted from an African green monkey (Rhim and Schell, 
1967). VERO cells were cultured in DMEM supplemented with 5% foetal bovine 
serum (FBS, F4135 Sigma Aldrich), 1% penicillin-streptomycin (10,000 U penicillin 
& 100 mg/ml streptomycin (P4333 Sigma Aldrich) at 5% CO2 at 37°C. VERO cells 
were cultured in 25cm2   flasks until 80% confluent. To do this, growth media was 
removed to allow cells to be washed with 5 mLs D-PBS. After which, 1 ml of 0.25% 
trypsin EDTA (25200-072, gibco life technologies) was added to the flask. The 
flask was then incubated at 37oC for 5 minutes. 10 ml of DMEM was added to 
inactivate the effects of trypsin. The cell suspension was transferred into a 15 ml 
tube and centrifuged at 2,000rpm for 10 mins. The supernatant was removed, 
and the pellet was resuspended in 10 ml of DMEM. The number of VERO cells 
were counted with haemocytometer using the trypan blue exclusion. 5 mLs of 






2.2. Parasite cultures  
The RH strain of Toxoplasma gondii was used throughout the work. Parasites 
were propagated as tachyzoites by serial passage in VERO cells cultured in DMEM 
supplemented with 5% FCS, 1% penicillin-streptomycin at 5% CO2 at 37°C.  
Parasites were harvested and then purified for use in experiments or re-
inoculated into VERO cells every 7 days. For T. gondii purification host cells were 
scraped from flasks with rubber disposable cell scraper. The cells were passed, 3 
times, through a 20mL syringe attached to a sterile blunt-ended needle. Cells 
were centrifuged for 10 minutes at 2000rpm at room temperature. PD-10 
Columns were prepared by removing the bottom plug and draining the storage 
buffer from the column. The column was washed with 5mL falcon tube. Parasites 
were resuspended in 5mL 1X D-PBS. 5mL of parasite solution was added to the 
column, then washes through with another 5mL PBS. The number of parasites 
was counted in 10 µL of filtered parasite solution. Finally, the parasites were 
centrifuged for 10 minutes at 2,000rpm, supernatant removed and resuspended 






2.3. Percentage monolayer destruction and free parasite counts 
VERO cells were seeded into 24 well plates (Corning 3524) at 2.5x104/well and 
incubated for 24 hours.  Thereafter cells were stimulated with cl-CD95L at 200, 
100 and 50ng/mL. 24 hours later cells were infected with T. gondii at 1x105/well. 
After 72 hours post infection the percentage of the VERO monolayer that has 
been destroyed was estimated using an Olympus BH2 microscope at X10 
magnification. An aliquot of supernatant was used to determine the extracellular 
parasite load.  
 
2.4. Bone marrow-derived macrophages (BMDM) 
Bone marrow-derived macrophages were obtained from healthy wild-type 
C57BI/6 mice aged between 8-16 weeks. Animals were culled by standard 
schedule 1 procedures of exposure to rising concentrations of CO2. Immediately 
afterwards hind femurs were removed and placed into sterile PBS for transport 
to the laboratory. Excess fat, muscle, and skin were removed. Thereafter bone 
marrow was flushed from the femur by repeated injecting, using a 2mL syringe 
and a 25-gauge needle, of the femur with complete media. Cells were passed 
through a 70μm cell strainer and centrifuged for 10 minutes at 1,500rpm. Cells 
were re-suspended, and a cell count performed using Trypan Blue (Trypan Blue 
Solution, 0.4%, ThermoFisher Cat No. 15250061). Bone marrow cells were 
seeded at 2x106/mL in a 6mL petri dish with the addition of 20ng/mL of M-CSF 
 41 
(Recombinant Murine M-CSF, PeproTech Cat No. 315-02). Every two days change 
media/M-CSF was replenished until cells were harvested on day 7.  
To harvest BMDM, media was first removed, and cells washed with PBS. Using 
PBS and a cell scraper, all cells were gently removed from the petri dish. Cells 
were collected by centrifuging at 1,200rpm for 5 minutes. Cells were 
resuspended and counted using Trypan Blue exclusion, thereafter BMDM were 
seeded in 96well flat-bottomed plates (CELLSTAR® Tissue Culture Plates, Greiner 











2.5. BMDM stimulation and infection 
After BMDM were seeded, the cells were stimulated with cl-CD95L at 200, 100 
and 50ng/mL. 24 hours later cells were infected with T. gondii at 1x105/well. After 
48 hours post infection the supernatant was taken off and the cell lysis buffer 
(Triton X-100, VVR International Ltd, Product no. 28817 at 0.1% in PBS) was added 
to the BMDM then both were frozen at -80oC. An aliquot of supernatant was used 
to determine the extracellular parasite load.  
2.5.1 Pre-exposure of BMDM 
Before stimulation with cl-CD95L and infection with T. gondii BMDM were 
exposed to different inhibitors.  
To inhibit IL-6 production, anti-mouse IL-6 (Bio Cell Cat No. BE0046) was used at 
120 ng/mL. Anti IL-6 was added during stimulation with cl-CD95L and the again 
24hrs later during T. gondii infection. For the inhibition of Arginase, Nω-hydroxy-
nor-Arginine (nor-NOHA) (Sigma) was used at 5mM. The arginase inhibitor was 
added during stimulation with cl-CD95L and the again 24hrs later during T. gondii 
infection. 
For the inhibition of cl-CD95L, mFas-Fc Chimera (R&D Systems Cat No. 435-FA) 
was added at 200ng/mL. The cl-CD95L inhibitor was added during stimulation 
with cl-CD95L and then again 24hrs later during T. gondii infection. For the 
inhibition of STAT6 (Sigma) was used at 0.2 mg/mL. The STAT6 inhibitor was 
added during stimulation with cl-CD95L and the again 24hrs later during T. gondii 
infection. 
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2.6. Cytokine assays- Mouse IL-1 beta and IL-6 Uncoated ELISA 
Cytokine ELISAs for IL-6, IL-1β were conducted using commercially available kits 
from Invitrogen (Cat no. 88-7064-88, 88-7013, respectively). 
 
In brief, the coating antibody was diluted adding 48µL of the antibody in 12mLs 
of coating buffer. 100µL of diluted coating antibody was then added to a 96 well 
ELISA plate (Corning Costar 9018) then left overnight at 4OC. Thereafter, plates 
were washed 3 times between each step. Plates were blocked with 200µL of 
ELISA Diluent at room temperature for 1 hour. A 2-fold serial dilution was 
performed for the top standard to make the standard curve for a total of 8 points. 
100µL of the samples were added to each well and 100µL of ELISA Diluent was 
then added to the blank well then left to incubate for two hours at room 
temperature. After which, 100 µL of diluted Detection Antibody was added to all 
wells. Plates were then sealed and incubated at room temperature for 1 hour.  
After the incubation, 100 µL of diluted Avidin-HRP was then added to each well 
for 30 minutes at room temperature. 1X TMB Solution was then added at 100 
µL/well and incubated at room temperature for 15 minutes. Finally, 50 µL of Acid 
Stop Solution was added to all wells. The plate was then read at 450nm and 






2.7. CellTiter-Glo® Luminescent Cell Viability Assay 
The frozen supernatants from the VERO cell experiments were used for CellTiter-
Glo® assays for the detection of ATP. 100 µL of each sample and media controls 
were added to a 96-well opaque plate. The plate was then left at room 
temperature for 30 minutes to equilibrate the plate. Thereafter, 100 µL of 
CellTiter-Glo® Reagent was added to each well. The contents were then mixed for 
2 minutes on an orbital shaker. Finally, the plate was left to incubate at room 
temperature for 10 minutes to stabilise luminescent signal. Luminescence was 
then recorded using GloMax® luminometer. 
 
2.8. LDH-Cytotoxicity Colorimetric Assay 
The frozen supernatants from the VERO cell experiments are used for 
Cytotoxicity assays for the detection of LDH. This began with transferring 10 
µL/well of each sample into of a clear 96-well plate (Corning Costar 9018). 
Thereafter, add 100 µL of the LDH Reaction Mix into each well and mix contents 
before incubating for 30 minutes at room temperature. Finally, measure the 





2.9. Arginase assay 
The cell lysates from the BMDM infections are first thawed and centrifuged for 2 
minutes at max speed to remove cells. 50µL of 10mM MnCl2/50mM Tris-HCl 
buffer (pH 7.5) and 50µL of lysate were added to an Eppendorf.  After being mixed 
thoroughly the samples were incubated for 10 minutes at 55oC for enzyme 
activation.  After which, 50 µL of 0.5M L-arginine substrate (pH 9.7) was added to 
the activated lysate and incubated for 1 hour at 37oC. To stop the reaction the 
acid-stop solution that was comprised of H2SO4 (96%), H3PO4 (85%), and H2O in a 
ratio of 1:3:7 was added to the samples. To each standard, 600uL of acid stop 
solution was added whereas 400µL was added to each sample. Finally 9% 
isonitrosopriopherone was added to develop colour. To each standard, 37.5 µL 
of isonitrosopriopherone was added and then 25µL was added to each sample. 
After which, all standards and samples were heated to 103°C for 45 minutes and 
allowed to cool in darkness for another 10 minutes. 200 µL aliquots are then 
added to a 96 well ELISA plate (Corning Costar 9018) and the plate is measured 









2.10. BMDM preparation for Phospho-Kinase Array  
BMDM were either left unstimulated or stimulated with 100ng/mL of cl-CD95L 
for 24 hours, after which BMDM were rinsed with PBS. BMDM were then 
solubilised at 1x107 cells/mL in Lysis Buffer 6 (R&D systems). Samples were 
pipetted up and down in order to resuspended BMDM and then rock the lysate 
for 30 minutes at 2-8oC. Samples were then centrifuged at 14,000 x g for 5 
minutes and then transferred to an Eppendorf tube.  
 
2.11. BCA Protein Assay  
Firstly, 10µL of each sample was pipetted into a 96 well plate (Corning Costar 
9018). 200µL of working reagent (Thermo scientific, Product No. 23227) was 
added to each well. Then standards were prepared and plate 10µL of each 
standard with 200µL of working reagent. The plate was then mixed thoroughly 
by being placed on a plate shaker for 30 minutes. Following this the plate was 
covered and incubated for 30 minutes at 37oC. Once the plate has cooled to room 
temperature the absorbance was measured 560nm on a plate reader. A standard 







2.12. Phospho-Kinase Array 
BMDM cell lysates were kept on ice prior to use. To begin protective sheets were 
removed from all membranes (Proteome Profiler, Phospho-Kinase Array, R&D 
Systems, Cat No. ARY003B). Each membrane was divided into two parts (A and B) 
and there was a total of 4 membranes. Each wells of an 8-Well Multi-dish was 
filled with 1.0mL of Assay Buffer 1, which served as a blocking buffer. After which, 
Part A and Part B were separated into the 8-Well Multi-dish and incubated on a 
rocking platform shaker for 1 hour. After incubation, the Assay Buffer 1 was 
aspirated and 1.0mL of the prepared samples were added to both parts A and B 
of each membrane. The plate was then incubated on a rocking platform shaker 
overnight at 2-8oC. During each wash step membranes were carefully removed 
and placed in a plastic wash container with 20mLs of Wash Buffer. At this step 
Parts A and B were washed together. Each set of membranes were washed on a 
rocking platform shaker for 10 minutes and repeated for a total of 3 washes. The 
8-Well Multi–dish was washed thoroughly with deionised water and dried. For all 
wells corresponding to Part A, 1.0mL of reconstituted Detection Antibody 
Cocktail A was added into Assay Buffer 1/ 2. For all Part B wells 1.0mL of 
reconstituted Detection Antibody Cocktail B was added into Assay Buffer 1/ 2. 
After, allowing excess Wash Buffer to drain from each membrane they were 
placed into appropriate wells. Then the plate was incubated on rocking platform 
shaker for 1 hour at room temperature. After incubation, the membranes were 
washed as described above however Part A and B were washed in separate 
containers. As the membranes were being washed, 1.0 mL of diluted 
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Streptavidin-HRP was added into Array Buffer 2/ 3 and then into each of the wells 
of the plate. Once again excess wash buffer was removed from membranes and 
they were placed back in corresponding well. Plates were incubated on a rocking 
platform shaker for 30 minutes at room temperature. After incubation once 
again, membranes and plate were washed as described above where Part A and 
B were washed in the same container. Each membrane was carefully removed, 
and the edge was blotted on a paper towel to drain excess Wash Buffer. Then 
each membrane was placed on a plastic sheet with its corresponding Part A and 
Part B end-to-end. After which, 1.0mL of Chemi Reagent Mix was added to each 
membrane set and incubated for 1 minute. After incubation the excess Chemi 
Reagent Mix was removed from each membrane. Then membranes were placed 
facing upwards on an autoradiography film cassette and exposed to X-ray film. 
Results were then analysed using ImageJ software to detect Pixel Density. Based 








2.13. Statistics  
Raw data was collected on Microsoft Excel workbooks. All data analysis was 
conducted using Prism 7 (GraphPad). Unpaired T-test was used to compare the 
means of two unmatched groups, assuming that the values follow a Gaussian 
distribution. Due to the data obtained during the study being parametric it was 
decided that an Unpaired T-test was the most suitable statistical method for 
comparing parasite counts during this study. A Two-way ANOVA determines how 
a response is affected by two factors. For this reason, a Two-way ANOVA was 
used to test the parametric data collected from all ELISA and Arginase assays; as 
parasite and cl-CD95L were two independent factors. A Tukey multiple 
comparison test was used as a post-test to compare every mean with every other 
mean. P values of <0.05 were taken as significant. 
 
2.14. Ethics 
All mice were culled by cervical dislocation schedule 1 procedure and tissue 
transported on ice to IC2 (Liverpool Science Park) where experiments were 
carried out. All mice were maintained in accordance to the Animal Scientific 
Procedures Act 1986 (ASPA). Tissues were obtained from excess breeding stocks 
maintained as part of a GM mouse colony and were collected as breeding stock 
animals were removed from the colony.  
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Chapter 3. Results 
 
To initially determine if cl-CD95L had an effect on T. gondii-host dynamics we 
tested the effects of cl-CD95L in well characterised VERO cells.  
 
3.1. cl-CD95L exacerbates T. gondii’s destructive capabilities in VERO 
cells 
We began by demonstrating the effect of pre-exposure to cl-CD95L on monolayer 
destruction in VERO cells following T. gondii infection. The level of VERO cell 
monolayer destruction was measured visually.  Figure 4 shows the reference 
images to illustrate how the grades of monolayer destruction were measured 
across treatments. The data collected from these monolayer destruction 
experiments is shown in Figure 5. From this data it can be seen that after infection 
with T. gondii, the percentage of destruction increases from 2% in 
uninfected/unstimulated to 14% in infected/unstimulated. Moreover, when cells 
are pre-exposed to cl-CD95L it was found that monolayer destruction was higher 
after T. gondii infection have higher levels when compared to unstimulated cells 
from 5% to 20% (P value <0.0001). Significant differences were also found 
between all uninfected and infected cells across when cells were stimulated with 
cl-CD95L in the range of 50, 100, and 200ng/mL (P value <0.0001). Finally, a 
significant difference was found between infected/unstimulated cells and with 
cells that were infected/stimulated with 100ng/mL of cl-CD95L (P value <0.05). 
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Figure 4. Reference images of different stages of VERO cell monolayer 
destruction (Zeiss Axiovert 25, X10 magnification) 
A) Shows VERO cells with no monolayer destruction due to T. gondii infection  












Figure 5. Percentage monolayer destruction intensifies after stimulation and 
infection 
VERO cells were either stimulated with doses of cl-CD95L as indicated. After 24 hours 
the cells were then infected with T. gondii at a MOI of 5 or left uninfected. After a further 
48 hours post infection the percentage of monolayer was estimated for each group by 
examination under a light microscope. Each treatment was performed in triplicate and 
data shown above presents 6 independent experiments. Data were analysed in 
GraphPad Prism using an Two way ANOVA to detect significant differences between 
stimulated and unstimulated cells compared to their infected counter parts 
(****P<0.0001). Significance was also found between in infected cell that were either 












3.2. Tachyzoite replication is amplified with the addition of cl-CD95L 
Having demonstrated a combined effect of T. gondii and cl-CD95L on monolayer 
destruction we next determined the effect of stimulation with cl-CD95L on T. 
gondii replication levels. VERO cells were stimulated with 100ng/mL of cl-CD95L 
and then infected with T. gondii. The number of parasites in the supernatant was 
determined after 48 hours of infection by manual counting using a 
haemocytometer. Figure 6 demonstrates that a significant increase in parasite 
replication occurs after stimulation (12x104/mL parasites) with cl-CD95L when 
compared to unstimulated (9x104/mL parasites) VERO cells. (P value <0.05). 
 
 
Figure 6. Free parasite counts with or without stimulation with cl-CD95L at 






VERO cells were either stimulated with 100ng/mL of cl-CD95L or left unstimulated. After 
24 hours the cells were then infected with T. gondii at a MOI of 5 or left uninfected. After 
a further 48 hours post infection the parasite number was counted for each group using 
a haemocytometer under a light microscope. Each treatment was performed in triplicate 
and data shown above presents 5 independent experiments. Data were analysed in 
GraphPad Prism using an Unpaired T test to detect significant differences between 















3.3. cl-CD95L increases cell viability with limited impact on 
cytotoxicity  
Parasite replication involves cell egress resulting in host cell destruction before 
infection of a new cell. Having demonstrated that the increase in monolayer 
destruction above might be caused by the increase in T. gondii replication 
because of cl-CD95L stimulation we sought to determine if cl-CD95L was causing 
these effects by an increase in cytotoxicity or by making host cells permissive. To 
test for increases in cytotoxicity we first measured ATP in the supernatants of 
cultures as a proxy for replicating host cells.  
These results demonstrate that before infection, as expected, there are high 
levels of cell viability (Figure 7 A). It can also be seen that there is a significant 
increase in cell viability in uninfected/stimulated cells when compared to 
uninfected/unstimulated (P value <0.05). In comparison, after infection with T. 
gondii the levels of cell viability, both unstimulated and stimulated with cl-CD95L, 
was reduced. In addition to this, VERO cells stimulated with 100ng/mL of cl-CD95L 
had a significant increase in cell viability under unstimulated/infected conditions 
(P value <0.001).  
To evaluate if cl-CD95L was altering the cytotoxicity of T. gondii during VERO cell 
infection we measured lactate dehydrogenase (LDH) in the supernatants. The 
results show a significant difference between cytotoxicity levels of uninfected 
and infected cells after stimulation to cl-CD95L (P value <0.001). A Significant 
difference was also found between uninfected/stimulated cells and cells which 
had been infected/stimulated (P value <0.05). 
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Figure 7. cl-CD95L does alter viability and cytotoxicity prior to T. gondii infection 
VERO cells were either stimulated with 100ng/mL of cl-CD95L or left unstimulated. After 
24 hours the cells were then infected with T. gondii at a MOI of 5 or left uninfected. After 
48 hours the supernatant were analysis. Each treatment was performed in triplicate and 
data shown above presents 5 independent experiments. Data were analysed in 
GraphPad Prism using a 2 way ANOVA. A) A Cell Titer-Glo assay was used to determine 
cell viability.  Significant differences were found between stimulated and unstimulated 
cells, which have not been infected (*P=0.05). Significant difference was also found 

















































Significant difference was found between uninfected cells that were unstimulated and 
their infected counter part (****P<0.0001). The same was found between infected cells 
that were stimulated with 100ng/mL of cl-CD95L and their infected counterpart 
(****P<0.0001). B) A LDH assay was used to determine the levels of cytotoxicity. 
Significant differences were found between stimulated and unstimulated cells, which 
had been infected (*P<0.05). Significant difference was also found between stimulated 
and uninfected cells and cells, which had been stimulated and infected (**P<0.05). 
Significant difference was also found between uninfected cells that were unstimulated 






































3.4. cl-CD95L alters BMDM responses during infection with T. gondii 
After demonstrating a change in response of VERO cells due to cl-CD95L exposure 
we wanted to further investigate if these responses were also present in BMDM 
and if there was a particular change in the immune response associated with it. 
As an initial experiment we investigated the impact of stimulation with cl-CD95L 
on parasite replication in BMDM by preforming parasite counts after 48 hours of 
infection.  
 
Figure 8.  Free parasite counts from BMDM stimulated with cl-CD95L and 
infected with T. gondii 
BMDM were either stimulated with 100ng/mL of cl-CD95L or left unstimulated. After 24 
hours the BMDM (105 per well) were then infected with T. gondii at a MOI of 5 or left 
uninfected. After a further 48 hours post infection the parasite number was counted for 
each group using a haemocytometer under a light microscope. Each treatment was 
performed in triplicate and data shown above presents 5 independent experiments. Data 
were analysed in GraphPad Prism using an Unpaired T test to detect significant 






BMDM were then used to determine if a cytokine response could be elicited 
following exposure to T. gondii and if differing doses of cl-CD95L could alter this. 
ELISAs were used to detect levels of IL-1 β and IL-6 from the supernatant. These 
were then used to determine the expected responses during stimulation and 
infection of BMDM to compare the inhibition of different pathways. 
To determine the effect of stimulation with cl-CD95L on T. gondii replication 
levels, BMDM cultures were stimulated with 100ng/mL of cl-CD95L and then 
infected with T. gondii. The number of parasites in the supernatant was 
determined after 48 hours of infection by counting using a haemocytometer. 
Figure 8 shows a significant increase in parasite counts after BMDM cultures have 
been stimulated with cl-CD95L when compared to unstimulated (P value <0.05). 
Using an ELISA kit the supernatants were analysed for the presence of IL-1 β. The 
data in Figure 9. A) shows that the production of IL-1β increases significantly by 
BMDM after infection using T. gondii tachyzoites. After using a 2-way ANOVA it 
has been shown that there was no significant difference between unstimulated 
and stimulated with cl-CD95L doses between 50-200ng/mL when comparing 
uninfected data, the same was true when comparing infected data. However, a 
significant difference was found when comparing uninfected and infected data 






The presence of IL-6 was also evaluated from the BMDM supernatants to 
determine the effect of cl-CD95L before and after infection with T. gondii. The 
data in Figure 9. B) illustrates that levels of IL-6 secretion by BMDM is significantly 
higher in BMDM that have been infected with T. gondii (P value <0.0001). Once 
infected, both unstimulated and stimulated BMDM produce increased levels of 
IL-6.  After using a 2-way ANOVA it has been shown that there was significant 













Figure 9. T. gondii and cl-CD95L synergistically alter cytokine responses. 
 
BMDM were stimulated using indicated doses of cl-CD95L. After 24 hours the BMDM 
(105 per well) were then infected with T. gondii at a MOI of 5 or left uninfected. After a 
further 48 hours supernatants were assayed for IL-1β and IL-6 using an ELISA kit. Each 
treatment was performed in triplicate and data shown above presents 5 independent 
experiments. Data were analysed in GraphPad Prism using a 2 way ANOVA to detect 
significant differences. A) IL-1β- Significant differences were found between BMDM 
which had been either stimulated or unstimulated and compared to their infected 
counterparts (****P<0.0001). B) IL-6- Significant differences were found between 
BMDM which had been either stimulated or unstimulated and compared to their 
infected counterparts (****P<0.0001). A significant difference was also found between 










The impact of cl-CD95L and T. gondii tachyzoites on the arginase activity of 
BMDM was determined using an arginase assay. The cell lysate was used to 
demonstrate arginase activity changes. Figure 10 shows that the arginase activity 
increases significantly after BMDM have been infected with T. gondii with both 
unstimulated and stimulated conditions (P value <0.0001). Additionally, with 
BMDM stimulation with cl-CD95L and 48hrs post infection the level of arginase 





Figure 10. Arginase assay using cl-CD95L at 100ng/mL after 48hours post 
infection. 
BMDM were stimulated using cl-CD95L at 100ng/mL. After 24 hours the BMDM (105 per 
well) were then infected with T. gondii at a MOI of 5 or left uninfected. After a further 
48 hours cell lysates were assayed using an arginase assay. Each treatment was 
performed in triplicate and data shown above presents 6 independent experiments. Data 
were analysed in GraphPad Prism using a 2-way ANOVA to detect significant differences 
between stimulated and unstimulated cells which had been infected (****P<0.0001) 
Significance was also found between uninfected and infected BMDM in both 
unstimulated and stimulated conditions (****P<0.0001). 
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3.5. The impact of inhibiting cl-CD95L during a T. gondii infection  
To better understand the effect cl-CD95L has on BMDM during a T. gondii 
infection we inhibited the ligand and compared the inhibited response to that of 
a normal BMDM-cl-CD95L response.  Figure 11. A) demonstrates that the 
inhibition of cl-CD95L causes a significant difference in the production of IL-6 by 
BMDM after infection with T. gondii when compared to expected value of 
infected BMDM stimulated with 100ng/mL (P value <0.05).  As expected, there 
was a significant difference in IL-6 production in uninfected BMDM, which had 
not been stimulated with cl-CD95L when compared to their infected counterpart 
(P value <0.0001). Similarly, this significant difference was also found in 
uninfected BMDM, which have been stimulated with 100ng/mL of cl-CD95L when 
compared to their infected counterpart (P value <0.0001). 
 
To evaluate the impact of inhibiting cl-CD95L on BMDM arginase activity during 
a T. gondii infection a cl-CD95L inhibitor was added during stimulation and then 
again when infected with T. gondii tachyzoites. The data in Figure 11. B) suggests 
that the inhibition of cl-CD95L causes a significant difference in arginase activity 
in stimulated BMDM when compared to expected stimulated values (P value 
<0.001). As expected in the vehicle control BMDM, there is a significant decrease 
in arginase activity in unstimulated BMDM when compared to stimulated BMDM 





To demonstrate the effect of inhibiting cl-CD95L on tachyzoite replication in 
BMDM, parasite counts were taken at 48 hours post infection using a 
haemocytometer. From the results in Figure 11. C) we can show that there is a 
significant decrease in parasite numbers when cl-CD95L is inhibited when 
compared to expected parasite numbers in stimulated BMDM (P value <0.05). As 
expected in the control BMDM cultures a significant increase in parasite counts 
is seen in infected/stimulated BMDM when compared to infected/unstimulated 




 Figure 11. The impact of a cl-CD95L inhibitor on BMDM function. A) IL-6 ELISA 
using a cl-CD95L inhibitor then stimulating with cl-CD95L dose stimulations at 
48hours post infection B) Arginase assay using cl-CD95L inhibitor with cl-CD95L 
doses after 48hours post infection C) Free parasite counts using cl-CD95L 





BMDM had cl-CD95L inhibited and were then stimulated using indicated doses of cl-
CD95L. After 24 hours the BMDM (105 per well) were then infected with T. gondii at a 
MOI of 5 or left uninfected. After a following 48 hours samples were analysed. Each 
treatment was performed in triplicate and data shown above presents 6 independent 
experiments for inhibited samples and a further 5 independent experiments for control 
samples. Data were analysed in GraphPad Prism using a 2-way ANOVA to detect a 
significant difference. A) The supernatants were analysed using an IL-6 ELISA Kit. 
Significant differences were found between infected and stimulated BMDM, which have 
a cl-CD95L inhibitor when compared to the expected values (*P<0.05). Expected values 
also show significant difference when comparing uninfected BMDM which have either 
been left unstimulated or stimulates with 100ng/mL of cl-CD95L when compared to 
infected counterparts (****P<0.0001). B) The cell lysates were analysed using an 
arginase assay. Significant differences were found between stimulated BMDM pre-
exposed to a cl-CD95L inhibitor when compared to stimulated BMDM with no inhibitor 
(**P<0.001). Significance is also seen between unstimulated and stimulated BMDM 
(*P<0.05). C) By preforming parasite counts, significant differences were found between 
stimulated BMDM, which have been pre-exposed to a cl-CD95L inhibitor when compared 
to expected values from non-inhibited BMDM (*P<0.05). A significant difference was 




























3.6. The inhibition of STAT6 thwarts BMDM responses 
To determine the role of STAT6 during stimulation with cl-CD95L and parasite 
infections with T. gondii we inhibited STAT6 and compared the results to the 
expected values. Initially the supernatant from BMDM, which had been pre-
exposed to a STAT6 inhibitor, were analysed for the presence of IL-6.  Figure 12. 
A) demonstrates how after STAT6 has been inhibited the level of IL-6 secretion 
by BMDM that have been stimulated with cl-CD95L decreases significantly when 
compared to the expected values (P value <0.001). This is also true in BMDM that 
are left unstimulated but pre-exposed to a STAT6 inhibitor when compared to 
expected values (P value <0.0001). As expected, there is a significant decrease in 
IL-6 production found between uninfected BMDM when compared to their 
infected counterparts, this is independent of stimulation with cl-CD95L (P value 
<0.0001).  
 
To evaluate the impact of inhibiting STAT6 on BMDM arginase activity during a T. 
gondii infection a STAT6 inhibitor was added during stimulation and then again 
when infected with T. gondii tachyzoites. The data in Figure 14. B) suggests that 
the inhibition of STAT6 leads to a significant reduction in arginase activity after 
infection with T. gondii. We found that when uninfected the level of arginase 
reduction in STAT6 inhibited BMDM was significant in both unstimulated and 
stimulated when compared to expected values (P value <0.05 for both 
unstimulated and stimulated). However, once infected the significant reduction 
in arginase activity is greater between STAT6 inhibited BMDM in both 
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unstimulated and stimulated counterparts when compared to expected values (P 
value <0.0001). As expected with non-inhibited BMDM, arginase activity 
increases after infection independent of stimulation with 100ng/mL of cl-CD95L 
(P value <0.0001). 
 
To determine the impact of inhibiting STAT6 on parasite replication in BMDM, 
parasite counts were taken at 48 hours post infection using a haemocytometer. 
This impact is illustrated in Figure 14 C), showing that when stimulated BMDM 
are pre-exposed to a STAT6 inhibitor the number of parasites decreases 
significantly when compared to expected values (P value <0.001). As expected, 
there is a significant increase in parasite numbers after BMDM have been 
stimulated with 100ng/mL of cl-CD95L when compared to unstimulated BMDM 




Figure 12. The inhibition of STAT6 shows the mechanical role of STAT6 in 
BMDM. A) IL-6 ELISA using a STAT6 inhibitor then stimulating with 100ng/mL of 
cl-CD95L at 48hours post infection B) Arginase assay using STAT6 inhibitor with 
100ng/mL of cl-CD95L after 48hours post infection C) Free parasite counts using 


























































































BMDM had arginase inhibited and were then stimulated using 100ng/mL of cl-CD95L. 
After 24 hours the BMDM (105 per well) were then infected with T. gondii at a MOI of 5 
or left uninfected. After a following 48 hours samples were analysed. Each treatment 
was performed in triplicate and data shown above presents 6 independent experiments 
for inhibited samples and a further 5 independent experiments for control samples. Data 
were analysed in GraphPad Prism using a Two-way ANOVA to detect significant 
differences. A) The supernatant was analysed using an IL-6 ELISA Kit. Significant 
differences were found between infected BMDM pre-exposed to a STAT6 inhibitor that 
have been stimulated or unstimulated when compared to their expected values 
(****P<0.0001). Significant differences have also been shown between uninfected 
BMDM that have been left unstimulated or stimulated when compared to their infected 
counterparts (****P<0.0001). B) The cell lysate was analysed using an arginase assay. 
Significant differences were found between stimulated and unstimulated BMDM, which 
have been pre-exposed to a STAT6 inhibitor when compared to expected values 
(*P<0.05/ ****P<0.0001). A significant difference has been found between uninfected 
BMDM and their infected counter parts (****P<0.0001). C) By preforming parasite 
counts, significant differences were found between stimulated BMDM which have been 
infected compared to stimulated and STAT6 inhibited (**P<0.001). A significant 
difference has also been found between parasite numbers from unstimulated and 















3.7. IL-6 secretion influences BMDM responses during infection 
Before investigating the effects that neutralising IL-6 has on T. gondii infections 
we first had to ensure the IL-6 neutralising antibody worked effectively. By 
carrying out an IL-6 EILSA using normal conditions as the control we were able to 
demonstrate the effectiveness of the neutralising antibody. Figure 13. A)  
illustrates that the anti-mouse IL-6 neutralising antibody (120ng/mL) works 
effectively by showing no levels of IL-6 detected from the samples. Significant 
differences were found between all infected BMDM with doses of cl-CD95L and 
left unstimulated when comparing normal conditions and when IL-6 is 
neutralised (P value <0.0001).  
 
To demonstrate the effect neutralising IL-6 has on the arginase activity of BMDM 
an IL-6 neutralising antibody was added to samples and compared to the 
expected values from an arginase assay. Figure 12. B) shows IL-6 neutralisation 
and infected BMDM that have been stimulated with 100ng/mL of cl-CD95L have 
significantly lover arginase activity in comparison to stimulated BMDM that are 
infected with no neutralising antibody added, which have been used as a control 
(P value <0.0001). This decrease in arginase activity can also be seen with infected 
unstimulated BMDM with anti-IL-6 when compared to their non-neutralised 
counter-part (P value <0.001). BMDM cultures display higher arginase activity 
when infected in comparison to their uninfected counterparts, this is 
independent of stimulation with cl-CD95L and IL-6 neutralisation (P value 
<0.0001). 
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In order to investigate how parasite replication is affected by the neutralisation 
of IL-6 secretion by BMDM parasite counts were taken at 48hrs post T. gondii 
infection. To determine the effect of stimulation with cl-CD95L has on T. gondii 
levels replication, BMDM were stimulated with 100ng/mL of cl-CD95L and then 
infected with T. gondii. The number of parasites in the supernatant was 
determined after 48 hours of infection by counting using a haemocytometer. 
Shown in Figure 12. C) are parasite counts taken from the IL-6 neutralised BMDM 
that have been stimulated with 100ng/mL of cl-CD95L and compared to expected 
parasite numbers. From this it is clear that when IL-6 is neutralised in stimulated 
BMDM parasite numbers decrease significantly (P value <0.0001). However, 
there was no significance found between unstimulated BMDM when IL-6 was 
neutralised when compared to expected values.  As expected in the vehicle 
control BMDM, there is a significant increase in parasite numbers when BMDM 





Figure 13. Anti-IL6 demonstrates IL-6 as a critical cytokine in BMDM 
functioning. A) IL-6 ELISA using anti-IL6 with cl-CD95L dose stimulations at 
48hours post infection B) Arginase assay using anti-IL6 with cl-CD95L doses after 
48hours post infection C) Free parasite counts using anti-IL6 on BMDM 

















BMDM were stimulated using indicated doses of cl-CD95L. After 24 hours the BMDM 
(105 per well) were then infected with T. gondii at a MOI of 5 or left uninfected. Anti-IL6 
was added during stimulation with cl-CD95L and again during infection. After a further 
48hrs samples were analysed. Each treatment was performed in triplicate and data 
shown above presents 6 independent experiments. Data were analysed in GraphPad 
Prism using a 2-way ANOVA to detect significant differences A) The supernatants were 
analysed using an IL-6 ELISA Kit significant differences were found between BMDM 
infected with T. gondii with does of cl-CD95L and left unstimulated when comparing 
control and when IL-6 is inhibited (****P<0.0001). B) The cell lysates were analysed using 
an arginase assay a significant difference was found between infected BMDM with anti-
IL6 which have been stimulated with 100ng/mL cl-CD95L when compared to non-
inhibited infected BMDM which has also been stimulated with 100ng/mL of cl-CD95L 
(****P<0.0001). A significant difference has been found between infected BMDM with 
anti-IL-6 without stimulation when compared to their non-inhibited counterparts 
(**P<0.001). Significant difference has also been found between uninfected BMDM 
when compared to infected BMDM independent of inhibitors and stimulation 
(****P<0.0001). C) By preforming parasite counts a significant differences was found 
between stimulated with no anti-IL-6 and stimulated with anti-IL-6 (***P<0.001). A 


























3.8. Arginase inhibition limits BMDM responses to T. gondii 
Previously in Figure 10 it has been demonstrated that Arginase is significantly 
increased after infection with T. gondii, particularly after stimulation with cl-
CD95L. In order to investigate the impact of arginase in relation to cl-CD95L and 
T. gondii BMDM were pre-exposed to an arginase inhibitor during stimulation 
and then again during infection.  
Before investigating the impact of inhibiting arginase on T. gondii infections we 
first had to ensure the arginase inhibitor worked effectively. By carrying out an 
arginase assay using normal conditions as the control we were able to 
demonstrate the effectiveness of the inhibitor. Figure 13. A) illustrates that the 
arginase inhibitor did not work effectively as even with a reduced detection level 
of arginase in comparison to expected value, the levels of arginase activity are 
still high. However, there is a significant difference between infected and 
simulated BMDM pre-exposed to an arginase inhibitor when compared to vehicle 
control BMDM (P value <0.0001). This significant difference can also be seen 
between infected and unstimulated BMDM when comparing pre-exposed to an 
arginase inhibitor to the expected values (P value <0.0001). As expected in the 
vehicle control BMDM, uninfected cells show a significantly lower arginase 
activity when compared to infected BMDM, independent of stimulation with cl-
CD95L (P value <0.0001). Following on from this, infected and stimulated BMDM 
display a significantly higher arginase activity when compared to unstimulated 
and infected BMDM (P value <0.0001).  
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The effect arginase has on IL-6 secretion by BMDM has been illustrated below 
using an IL-6 ELISA kit. From Figure 13. B) it has been shown that there is a 
significant difference between the levels of IL-6 produced by arginase inhibited 
BMDM that have been stimulated with 100ng/mL of cl-CD95L when compared 
with stimulated BMDM, which have not been inhibited (P value <0.05). As 
expected in the vehicle control BMDM, there is a significant difference in IL-6 
production between uninfected and infected BMDM independent of stimulation 
with cl-CD95L and inhibitors (P value <0.0001).  
 
To better understand the effect of inhibiting arginase on parasite replication in 
BMDM, parasite counts were taken at 48 hours post infection. Figure 13. C) 
illustrates that when arginase is inhibited in unstimulated BMDM, there is no 
significant difference in parasite numbers when compared to expected values. 
However, there is a significant decrease in parasite counts when arginase is 
inhibited in BMDM stimulated with 100ng/mL of cl-CD95L when compared to 
control values (P value <0.05). As expected in normal conditions there is also a 
significant increase in parasites numbers found in BMDM stimulated with 




Figure 14. The inhibition of Arg-1 showing the role of Arg-1 in BMDM. A) 
Arginase assay using arginase inhibitor with 100ng/mL of cl-CD95L at 48hours 
post infection B) IL-6 ELISA using an arginase inhibitor then stimulating with 
100ng/mL of cl-CD95L at 48hours post infection C) Free parasite counts using 





























































































BMDM were stimulated using 100ng/mL of cl-CD95L. After 24 hours the BMDM (105 per 
well) were then infected with T. gondii at a MOI of 5 or left uninfected. After a following 
48 hours, samples were analysed. Each treatment was performed in triplicate and data 
shown above presents 6 independent experiments. Data were analysed in GraphPad 
Prism using a Two-way ANOVA to detect significant differences. A) The cell lysates were 
analysed using an arginase assay. A significant difference was found between stimulated 
and unstimulated cells, which had been infected and pre-exposed to an inhibitor and 
compared to expected values (****P<0.0001). A significant difference has also been 
found between uninfected BMDM when compared to their infected counterparts 
(****P<0.0001). B) The supernatant was analysed using an IL-6 ELISA Kit. A significant 
difference was found between stimulated BMDM, which have been pre-exposed to a cl-
CD95L inhibitor when compared to stimulated BMDM that were not inhibited (*P<0.05). 
Significant differences were also found between uninfected BMDM and their infected 
counter parts (****P<0.0001). C) By preforming parasite counts a significant difference 
was found between BMDM stimulated with 100ng/mL of cl-CD95L which had been pre-
exposed to an arginase inhibitor when compared to expected values (*P<0.05). 
Significant differences were also found between unstimulated and stimulated BMDM, 





















3.9. cl-CD95L leads to enhanced phospho-kinase expression  
During our previous investigations there has been differences in responses 
between stimulated and unstimulated BMDM regardless of infection with T. 
gondii. To determine if these differences were caused ultimately by cl-CD95L 
stimulation a Proteome Profiler was utilised which assesses protein expression in 
cell lysates. A Phospho-Kinase Protein Array was selected to identify changes to 
the global profile within cellular signalling pathways which may account for the 
phenotypic differences we identified previously. Data was analysed using imaging 
software and presented in a heat map format as pixel densities. Striking 
differences in protein expression can be seen between unstimulated and 
stimulated BMDM in Figure 15. 
A variety of proteins found to be upregulated by cl-CD95L are linked to signalling 
pathways. This included the upregulation of sphingosine 1 phosphate (S1P) 
signalling pathways which have previously been shown in Th17 cells stimulated 
with cl-CD95L. Similarly, Ca2+ signalling pathways have also been upregulated 
with the addition of cl-CD95L. This pathway has been shown in previous studies 
to be linked with endothelial transmigration due to cl-CD95L stimulation (Tauzin 
et al., 2011). 
Figure 15 also shows that stimulation with cl-CD95L leads to upregulation of the 
JAK/STAT pathway in macrophages. We demonstrated that both STAT5 and 
STAT3 were upregulated after stimulation with cl-CD95L. Figure 15 demonstrates 
that STAT3 has the most prominent upregulation of all the STAT proteins, after 
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cl-CD95L stimulation. The activation of the JAK/STAT cascade is vital for the 
expansion of MDSCs (Nagata et al., 2019).  
The Phospho-kinase microarray showed the upregulation of MAPK pathway after 
stimulation of macrophages with cl-CD95L. The MAPK pathways has been found 
to be a key regulator of MDSC function (Trikha and Carson, 2014).  The mTOR 
pathway has been shown to promotes MDSC recruitment, regulate induction of 
MDSCs, and strengthen their immunosuppressive responses (Zhang et al., 2017). 
Figure 15 shows that cl-CD95L causes upregulation of the VEGF pathway. The 
activation of the VEGF pathway is key for the infiltration of MDSCs (Yang, Yan and 





Figure 15. Heatmap illustrating the variation in protein expression by BMDM 
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BMDM were harvested and after 24 hours either stimulated using 100ng/mL of cl-CD95L 
or left unstimulated. After a following 24 hours samples were analysed for protein 
concentration using a BCA Protein Assay Kit. Once protein concentration was 
determined the same concentration was used to detect the difference in protein 
expression in each sample using a Phospho-Kinase Array. Each treatment shown above 
presents 2 independent experiments. Pixel Density was analysed using ImageJ software. 
Data was then presented by a heat map shown was created using the averages from the 


















Chapter 4. Discussion  
 
Approximately 1-2 billion people are infected with T. gondii globally, making it 
one of the most successful protozoan parasites. In the United States alone 10-
40% of all adults with AIDS are latently infected with T. gondii and one-third of 
those with a latent infection will go on to develop Toxoplasmic encephalitis (Luft 
and Remington, 1992). T. gondii infections cause fatal and devastating brain 
disease and eye disease including ocular toxoplasmosis. Ocular disease is more 
severe in continents like South America due to the virulent genotypes of the 
parasite present in this region (Carneiro et al., 2013). In developing countries, the 
major route of infection with T. gondii is through untreated drinking water as 
opposed to in the Western world there the main infection route is through raw 
or uncooked meat (Petersen, Kijlstra and Stanford, 2012). 
The current treatment course for T. gondii infection is associated with high levels 
of drug toxicity and often requires prolonged treatment courses ranging between 
weeks to over a year. The prolonged treatment time and the risk of relapsing is 
due to T. gondii tissue cysts and the lack of an efficacious drug capable of 
targeting this stage. There are many challenges in developing effective T. gondii 
treatments which include elimination of tissue cysts, decreasing toxicity, and 
practical for use in countries with poorly developed healthcare systems (Alday 
and Doggett, 2017). 
 
 84 
There are currently no licensed vaccines against T. gondii available for human 
use. There is only one commercially available vaccine to protect against 
congenital infections in sheep. The vaccine Toxovax is based on the live 
attenuated S48 strain. Unfortunately, Toxovax causes adverse effects in pregnant 
ewes, has a short shelf-life and has a great expense. Due to Toxovax being a live 
attenuated vaccine it may revert to pathogenicity and is therefore not suitable 
for human use (Kur, Holec-Gąsior and Hiszczyńska-Sawicka, 2009). In the absence 
of an effective, non-toxic treatment, we believe it is critical to better understand 
the immunogenic ligand cl-CD95L, that may increase the pathogenicity of T. 
gondii during mammalian infections. This understanding of the immune 
environment created during infection could facilitate future success in host-
directed therapeutics in the treatment of T. gondii. Host-directed therapeutics 
act upon the host-mediated responses to change the local environment in which 
the parasite exists to make it less favourable for parasite replication.  To better 
understand the impact of cl-CD95L on T. gondii infections experiments were 
preformed using both VERO cells and BMDM. 
CD95 is a ubiquitously expressed death receptor which is involved in a plethora 
of physiological and pathological apoptotic processes. The interaction between 
CD95 and its ligand induces the recruitment of signaling moclecules initiating a 
signalling cascade ultimately leading to cell death (Ricci-Vitiani et al., 2000). 
Conversley, cl-CD95L does not trigger an apoptotic signalling pathway. cl-CD95L 
has been found to promote endothelial transmigration of T-cells aggravating 
clinical symptoms of experimental Lupus in mice (Poissonnier et al., 2016). 
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To begin to investigate the role of cl-CD95L we utilised host VERO cells. The major 
finding of the VERO cell experiments was that 100ng/mL of cl-CD95L amplified 
the levels of monolayer destruction after T. gondii infection while also leading to 
increased tachyzoite numbers. Previous studies have shown that T. gondii 
processes and degrades caspase 8 which is a key initiator of apoptosis. The 
degradation of caspase 8 ultimately blocks CD95-mediated apoptosis which 
signalling is independent of the host mitochondria apoptogenic functions (Vutova 
et al., 2007). However, T. gondii has also been shown to inhibit cell apoptosis by 
interference with the mitochondrial amplification loop (Hippe et al., 2008). These 
studies mirror our monolayer destruction data, that when VERO cells are infected 
with T. gondii the levels of destruction are less than that in our cl-CD95L 
stimulated/infected groups.  
 
From monolayer data alone, the increase in monolayer destruction in infected 
cells after stimulation with cl-CD95L could be due to apoptosis. However, after 
obtaining parasite counts, we believe that cl-CD95L leads to an increase in 
parasite replication, which results in the destruction of the cell monolayer. Prior 
studies support these findings, showing that cl-CD95L fails to elicit apoptotic 
signalling pathways. Similar findings have also been reported demonstrating that 
cl-CD95L downregulates proapoptotic activity in mice (Schneider et al., 1998), 
with the cleaved ligand instead inducing pro-inflammatory signalling pathways 
(Poissonnier et al., 2016).   
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Further support of this was evident when performing the VERO cell experiments 
it was also discovered that stimulation with cl-CD95L also caused increased cell 
viability. This effect was found when comparing non-infected cells and also when 
comparing cells infected with T. gondii. Demonstrating that cytotoxicity also 
decreases when VERO cells are infected and stimulated with cl-CD95L. This is not 
the first time cl-CD95L has been linked to cell survival and growth. Previously it 
has been found that stimulation with cl-CD95L leads to the upregulation of the 
sphingosine-1-phosphate (S1P) pathways in Th17 cells (Poissonnier et al., 2016). 
Studies have shown that S1P has a role as a survival factor with its ability to rescue 
cells from apoptosis, in addition to its role in immune cell differentiation, 
migration and function (Reimann et al., 2015). Previous research has also found 
cl-CD95L to be is a powerful indicator of metastatic dissemination in breast 
cancer (Malleter et al., 2013). 
 
Despite the important role of cell lines in research evidence has accumulated that 
cell lines are frequently contaminated or misidentified. In labs in Europe, the 
United States and Asia it has been found that at least 15% of cell lines are 
contaminated or misidentified. Misidentification can often go unidentified due to 
cells being morphologically similar. While it has been found that between 5-10% 
of cell culture studies have used cells which have mycoplasma contamination 
(Lorsch, Collins and Lippincott-Schwartz, 2014). While cell lines are a powerful 
tool, caution should be taken when using them in place of primary cells. Although 
cell lines maintain features close to primary cells it may be difficult to determine 
as primary cell functions are often not understood in their entireity. Furthermore, 
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over time serial passage of cell lines can further cause genotypic and phenotypic 
variation leading to heterogeneicty in cultures (Kaur and Dufour, 2012). 
Therefore, VERO cells may not adeuately represent results seen in primary cells. 
For these reasons after our preliminary studies using VERO cells, we furthered 
the investigation by using more immunologically significant BMDM.  
 
Similar to the VERO cell experiments, we found that the stimulation of BMDM 
with cl-CD95L increases parasite burden. Therefore, we believe that cl-CD95L 
stimulation is detrimental to the host cell and favours parasite replication during 
T. gondii infection. To determine that the changes in BMDM responses seen was 
directly caused by stimulation with cl-CD95L we added a cl-CD95L inhibitor, 
soluble CD95-Fc chimeric protein, to our experiments. In the cl-CD95L inhibited 
treatments there was a decrease in tachyzoite numbers when compared to 
stimulated BMDMs. Similarly, during infection with T. gondii the levels of IL-6 and 
arginase levels decrease when cl-CD95L is inhibited. These inhibition experiments 
demonstrate that the upregulation of IL-6, arginase and parasitaemia are directly 
linked to BMDM stimulation with cl-CD95L.  
A major finding of these experiments was the increased production of IL-6 after 
stimulation with cl-CD95L during infection. Previous studies have demonstrated 
that T. gondii infected patients have a twofold higher level of IL-6 when compared 
to healthy individuals (Matowicka-Karna, Dymicka-Piekarska and Kemona, 2009). 
During experiments with KO mice, studies have shown that in the absence of IL-
6, mice are unable to initiate a rapid proinflammatory response to T. gondii. It 
has been suggested that increased mortaility evident in IL-6 KO mice is linked to 
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increased parasite burdens (Jebbari et al., 1998). Contradictory to this, studies 
has found that pre-treatment of mouse BMDM with IL-6 leads to enhanced levels 
of T. gondii replication (Beaman, Hunter and Remington, 1994). Therfore we 
propose that the increase in IL-6 production after cl-CD95L stimulation may be a 
cause of the increased parasitemia we previously demonstrated in this study. 
After demonstrating an effect of cl-CD95L stimulation on the secretion of IL-6 by 
BMDMs we further investigated the effects of neutralising IL-6 on BMDM. The 
levels of arginase activity in cell lysates of IL-6 neutralised BMDM were examined. 
As previously found, the levels of arginase activity increase significantly after 
infection. By the same assay we also demonstrated that after the neutralisation 
of IL-6 the levels of arginase decreased significantly in both stimulation and 
unstimulated BMDM when compared to the non-neutralised counterparts, the 
same was also true for parasite numbers. This may be due to IL-6 enhancing the 
expression of arginase 1 and therefore once IL-6 is inhibited the production of 
arginase decreases (Qualls et al., 2010). This lower parasite burden has also been 
demonstrated in other studies in which IL-6 has been neutralised during in vivo 
T. gondii infections of C57BL/6 mice (Rochet et al., 2015). From this data it can be 
summarised that when IL-6 is neutralised in BMDM this does not lead the 
expected rise in parasite counts seen after cl-CD95L stimulation.  Therefore, cl-





From our study we also demonstrated that stimulation with cl-CD95L during a T. 
gondii infection lead to an increase in arginase production in murine BMDM. Both 
arginase and iNOS share the same substrate, L-arginine with arginase hydrolysing 
L-arginine to L-ornithine and urea. The production of L-ornithine favours the 
growth of T. gondii while also being a precursor for the synthesis of L-glutamine, 
L-proline and polyamines. These polyamines are also essential for the 
proliferation of both cells and parasites. iNOS synthesises vast amounts of NO 
through the oxidation of L-arginine (Li et al., 2012). NO is a major effector 
molecule in macrophage-mediated cytotoxicity and for this reason is considered 
to be a defence mechanism against T. gondii (Adams et al., 1990). However, the 
potential parasite killing effects of high NO levels are limited by arginase 
competition with iNOS for the L-arginine. Interestingly, T. gondii is capable of 
infecting BMDM and reducing the production of NO (Lüder et al., 2003). We 
speculate that T. gondii along with cl-CD95L increases levels of arginase while 
decreasing parasite limiting NO production. Furthermore, the combined effect of 
parasite and cl-CD95L may synergise to directly impact host cells ability to reduce 
parasitemia.  
 
Macrophages can be divided into two functionally distinct subsets, classically 
activated macrophages (CAM) and alternatively activated macrophages (AAM) 
depending on the cytokine environment to which macrophages have been 
exposed. Exposure to IFN-γ and LPS will lead to CAMs which promote 
inflammation and killing of intracellular pathogens. While exposure to IL-4, IL-10, 
or IL-13 leads to AAMs that regulate inflammation and promote tissue repair 
 90 
(Classen, Lloberas and Celada, 2009). During this study we demonstrated both an 
inflamatory IL-6 response commonly seen in CAMs while also showing a rise in 
the arginase response, a hallmark of AAMs. Therfore, we began to speculate how 
this seemingly paradoxical event could occur.  
This induction of AAM hallmarks within a CAM macrophage would allow an 
efficient self-regulation of both cytotoxic and proinflammatory responses during 
the progression of an immune response. However, it has been shown in mice that 
BMDM lacking the expression of Arg1 have increased clearance of pathogens. 
Furthermore, the production of Arg1 in CAMs prevents competition by NO 
weakening BMDM ability to control T. gondii infections(El Kasmi et al., 2008). 
Subsequent studies have been able to demonstrate that murine macrophages 
populations can respond to different stimuli and simultaneously express both 
CAM and AAM phenotypes in response to a T. gondii infection (Patil et al., 2014). 
Thus expression of arginase within a majority CAM population would serve to 
limit pathology while controlling parasite load. 
Another explanation maybe that cl-CD95L induces an MDSC-like phenotype in 
murine BMDM. It has been shown that IL-6 induces SOCS3 dysfunction and 
activates the JAK/STAT signalling pathway promoting the ampification of MDSCs 
during  in vitro and in vivo studies of cancer (Jiang et al., 2017). Previous studies 
have also demonstrated that in SLE patients the accumulation of IL-6 promotes 
the expression of arginase by MDSCs (Wu et al., 2016) (Flynn and Legembre, 
2016). The increase in arginase production by MDSCs could therfore lead to the 
increase in parasitemia which we have previously seen while increases in IL-6 
promote an MDSC like-phenotype.  
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cl-CD95L has also been shown to cause a pro-inflammatory response rather than 
triggering an apoptotic signalling pathway, therefore these conditions may allow 
for unregulated parasite growth (Poissonnier et al., 2016). It has also been 
suggested that cl-CD95L may have a role in MDSC differentiation. Moreover there 
is a previous mechanistic link reported between MDCSs function and Arg-1 
upregulation (Gabrilovich and Nagaraj, 2009). Additionally, it has also been 
demonstrated that exposure to T. gondii peroxiredoxins  elevates Arg-1 
production by driving the activation of alternatively activated BMDM (Marshall 
et al., 2011).  
 
Before investigating impact of arginase inhibition during a T. gondii infection of 
BMDM it was first crucial to investigate the effectiveness of the inhibitor. It was 
discovered through performing an arginase assay that the inhibitor caused only 
a small decrease in the levels of arginase activity (Figure 13. A). As expected, and 
previously seen during this study, IL-6 levels increased after infection regardless 
of stimulation or inhibition. Even in light of the effectiveness of the arginase 
inhibitor, there was a small decrease in IL-6 secretion found in stimulated and 
arginase inhibited BMDM after infection when compared to their non-inhibited 
counterpart. During this investigation it was also found that stimulated BMDM 
with arginase inhibited had reduced parasite counts in comparison to the non-
inhibited counterparts. This may be due the lack of arginase and therefore its 
ability to deplete L-arginine, which is known to inhibited IL-6 (Fan et al., 2009).  
The decrease in parasite counts in arginase inhibited cultures also demonstrates 
that the minimal effect of the arginase inhibitor was biologically significant. The 
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cl-CD95L driven increase in parasite load leads to increased destruction of cells 
causing higher levels of IL-6. IL-6 has been found to initiate an inflammation 
amplification loop through the MDSC like phenotype in BMDM. An MDSC like 
phenotype also increases levels of arginase 1 leading to the increased catabolism 
of L-arginine. This depletion of L-arginine has been shown to promote the growth 
of multiple species of protozoan parasites (Iniesta, Gómez-Nieto and Corraliza, 
2001). The increase in arginase production seen after BMDM stimulation with cl-
CD95L could suggest the alternate activation of the macrophages. However, AAM 
would also cause an anti-inflammatory response not evident by the rise in IL-6. 
In our study we consistently demonstrated a proinflammatory response in 
BMDM due to stimulation with cl-CD95L and T. gondii infection, as well as 
increased levels of arginase production after stimulation with cl-CD95L. Taking 
this proinflammatory response together with upregulated arginase production 
into consideration we speculate that stimulation with cl-CD95L leads to BMDM 











Upstream of Arg1 lies the transcription factor STAT6, studies have shown that the 
induction of the Arg-1 gene by IL-4 requires the direct interaction of the Arg-1 
promoter with STAT6 (Gray et al., 2005). To better understand the role of STAT6 
in the functioning changes caused by cl-CD95L we used an inhibitor in our studies. 
The major finding of these STAT6 inhibited experiments was the levels of both IL-
6 and Arg1 dropped to undetectable levels even after infection with T. gondii and 
stimulation with cl-CD95L. Similarly, parasite counts decreased dramatically in 
inhibited/stimulated cultures when compared to non-inhibited/stimulated. The 
data demonstrates that the inhibition of STAT6 also eliminates the upregulation 
previously seen in IL-6 and Arg1 after stimulation with cl-CD95L. It has been well 
documented that T. gondii inject ROP16 kinase into host cells where it activates 
STAT6 (Butcher et al., 2011) avoiding host immunity. It has also been shown that 
STAT6 KO mice are less susceptable and exhibits lower parasite numbers when 
orally challanged with T. gondii compared to wild type mice (Jensen et al., 2013). 











To gain a deeper understanding of the impact of cl-CD95L on signalling in BMDM 
without infection with T. gondii we performed a protein signalling array.   
A major finding in the investigation is the upregulation of signalling pathways 
integral to MDSCs, this includes the increased expression in the JAK/STAT 
pathway. Studies have shown most signalling pathways that are triggered by 
MDSCs converge on STAT3 and JAK protein family members (Pyzer et al., 2016). 
The upregulation of STAT3 and STAT5 allows regulation of MDSC expansion, 
during our study the stimulation of BMDM with cl-CD95L leads to increased STAT 
expression, as demonstrated by the effects of STAT6 inhibition.  
The Akt signalling pathway was upregulated through BMDM stimulation with cl-
CD95L. Akt exists as three isoforms in mammals, Akt1 is widely distributed 
through tissues, while Akt2 is found in fat and muscle cells, and Akt3 is present 
prefominantly in the brain. The Akt pathways regulates a multitude of biological 
processes, these incude cell growth and proliferation (Hers, Vincent and Tavaré, 
2011). ATK can lead to the activation of mTOR, mTOR belonging to a group of 
Ser/Thr protein kinases of the PI3K superfamily (Liu et al., 2009). We also 
demonstrated that stimulation of BMDM with cl-CD95L leads to the upregulation 
of mTOR. mTOR plays a pivotal role in the regulation of cell growth and 
proliferation by monitoring nutrient availability, cellular energy levels, oxygen 
levels, and mitogenic signals. mTOR has previous links with cancer, as activation 
of mTOR provides a growth advantage to tumour cells by promoting protein 
synthesis (Liu et al., 2009). The Ras-ERK and PI3K-mTOR pathways are also critical 
in controlling cell survival, differentiation and motility. ERK which is a MAPK 
functions as a major effector of the Ras oncoprotein. These pathways can 
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negatively affect each other’s activity or activate signalling (Mendoza, Er and 
Blenis, 2011). 
During BMDM stimulation with cl-CD95L we found an increased expression of 
members of the VEGF signalling pathway. Previous research has demonstrated 
that VEGF can decrease apoptosis caused by CD95 interacting with its ligand 
(Berkkanoglu et al., 2004). VEGF expression has also been shown to promote 
tumour angiogenesis and immunosuppression in ovarian cancer. This is 
consistent in studies analysing triple-negative breast cancer where an inverse 
correlation between VEGF and T-cell function has been found. A correlation has 
also been found between VEGF expression and MDSC infiltration (Horikawa et 
al., 2017). Again highlighting the potential link between cl-CD95L and MDSC 
induction. 
Importantly, the data we obtained from our array mirrored studies that identified 
signalling pathways involving cl-CD95L previously. Previous studies have shown 
that cl-CD95L up regulates c-yes and PI3K-driven signalling pathways, these 
pathways are used by cl-CD95L to promote cell migration (Tauzin et al., 2011). A 
mechanistic link has previously been demonstrated in triple-negative cancers 
between c-Yes and PI3K pathways (Malleter et al., 2013). In these studies cl-
CD95L levels are elevated and cl-CD95L has therefore been demonstrated to be 
is a potent marker for metastatic dissemination (Legembre et al., 2014). Another 
key cl-CD95L pathway which we also found to be upregulated in our study is the 
calcium signalling pathway through expression of PLC-y1. Previous studies have 
shown that both the activation of the PI3K pathways and the rise of intracellular 
calcium play a major role in achieving cell motility  (Tauzin et al., 2011). 
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This understanding of the effect cl-CD95L has during T. gondii infections is critical 
due to links between the parasite and the activation of matrix metalloproteases 
(Seipel et al., 2010). CD95L is cleaved by MMPs during infection with T. gondii 
leading to more cl-CD95L circulating in the host amplifying an inflammatory loop. 
Figure 16 illustrates the pathways found to be upregulated during our study when 
macrophages are infected with T. gondii and stimulated with cl-CD95L. It was 
demonstrated that a proinflammatory response was still present in macrophages 
while there is also an upregulation of Arg-1 in a STAT6 dependent manor. This 
study shows that when IL-6, Arg-1 and STAT6 are upregulated the conditions are 
favourable for parasite replication.  
 
Figure 16. Diagram showing interactions during macrophage infection with T. 




To refine our hypothesis that cl-CD95L is causing non-apoptotic signalling, a more 
sensitive assay could be used such as PI staining. Using PI staining measurement 
by flow cytometry it would also be possible to associate cell viability with parasite 
invasion if we were also capable of using a fluorescent strain of T. gondii. 
Alternatively, monitoring caspase activity which sits downstream of CD95 
apoptotic signalling would also verify that known CD95 signals were being 
altered. 
 
Expanding the pool of samples analysed by the Phospho-kinase array to 
demonstrate the pathways upregulated during a T. gondii infection as well as 
stimulation with cl-CD95L. Work leading on from this would include an element 
of validating individual targets which are implicating in MDSC biology including 
IFN-γ, TGF- β, and IL-17. This would complement studies, to allow for a more 
robust identification of MDSCs, flow cytometry should be used to phenotype the 
cells population. 
 
Combining those studies could lead to an In vivo study to measure levels of cl-
CD95L circulating in mice during a T. gondii infection, levels of cl-CD95L can be 
analysed using an ELISA. Following on from this it would also be interesting to 
inhibit cl-CD95L with mFas-Fc Chimera in vivo to investigate if this creates a less 





Chapter 5. Concluding remarks  
 
The overarching aim of this study was to identify what, if any, mechanisms by 
which cl-CD95L impacted host cell survival during a T. gondii infection. Previous 
studies have demonstrated that cl-CD95L prevents apoptosis and promotes cell 
viability and in both cancer and lupus, cl-CD95L has detrimental effects on host 
immune responses. 
The aim of our study was to determine if cl-CD95L also has an adverse effect on 
host immunity during a T. gondii infection. We demonstrated that cl-CD95L 
stimulation leads to a greater pro-inflammatory response then that caused by T. 
gondii alone. We also determined that cl-CD95L stimulation upregulates Arg-1 
expression in a STAT6 dependent manner. Taking these individual observations, 
we speculate that cl-CD95L stimulation primes BMDM to behave like MDCS. In 
our study we have shown that the stimulation of BMDM with cl-CD95L leads to 
an MDSC-like phenotype. Figure 16 illustrates the similarities in traditional MDSC 





  Common in both models 
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Figure 17. Illustrating similarities between cl-CD95L treated BMDM and MDSCs 
A) Depicts the BMDM response following cl-CD95Lstimulation incorporating both 
phosopho-kinase array results from infected/stimulated experiments  
B) A general MDSC response is shown with both effector and promoter cytokines 
alongside intracellular signalling factors which have been previously been associated 
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1.1. Recipes  
1.1.1 ELISA 
Wash Buffer 
 KCl- 0.2g 
 NaCl- 8g 
 Na2HPO4- 1.44g 
 KH2PO4- 0.24g 
 DI water- 800mLs 
 Tween-20- 500µLs 
 
Bicarbonate/Carbonate Coating Buffer  
 Na2CO3- 3.03g 
 NaHCO3- 6.0g 
 DI water – 1,000mLs 
 
Diluent  
 NaCl- 8.0 g 
 Na HPO- 1.16 g   
 KH PO- 0.2 g  
 KCl- 0.2 g 
  Add deionized water to 1.0 L 
Acid Stop Solution 




1.1.2. Arginase assay 
Arginase Activator (50mM) 
 Tris-HCl- 7.88g 
 DI water- 1,000mLs 
 Set pH to 7.5 
 
10mM MnCl2/ 50mMTris-HCl  
 MnCl2- 0.126g 
 Tris-HCl- 100mLs  
 
L-arginine Substrate  
 L-arginine- 0.871g  
 DI water- 10mLs  
 
Acid-stop Solution 
 H2SO4- 1mL 
 H3PO4- 3mLs 
 DI water- 7mLs 
 
Alpha-ISPF  
 α- ISPF- 0.09g 
 100% ethanol- 1mL 
 
 
 
 
